WO2006021350A1 - Novel agent for treating keratin fibres - Google Patents

Novel agent for treating keratin fibres Download PDF

Info

Publication number
WO2006021350A1
WO2006021350A1 PCT/EP2005/008875 EP2005008875W WO2006021350A1 WO 2006021350 A1 WO2006021350 A1 WO 2006021350A1 EP 2005008875 W EP2005008875 W EP 2005008875W WO 2006021350 A1 WO2006021350 A1 WO 2006021350A1
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
composition according
protein
hair
derivatives
Prior art date
Application number
PCT/EP2005/008875
Other languages
German (de)
French (fr)
Inventor
Gabriele Weser
Marlene Henke
Original Assignee
Hans Schwarzkopf & Henkel Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hans Schwarzkopf & Henkel Gmbh & Co. Kg filed Critical Hans Schwarzkopf & Henkel Gmbh & Co. Kg
Publication of WO2006021350A1 publication Critical patent/WO2006021350A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/645Proteins of vegetable origin; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/12Preparations containing hair conditioners
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/88Two- or multipart kits
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/02Preparations for cleaning the hair
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/06Preparations for styling the hair, e.g. by temporary shaping or colouring

Definitions

  • the present invention relates to an agent for the treatment of keratinic fibers, which contains at least one protease and at least one further component which is selected from protein hydrolysates as well as vitamins, provitamins and vitamin precursors and derivatives thereof. Furthermore, the invention relates to corresponding uses and methods for the treatment of keratinic fibers.
  • Human hair is today treated in a variety of ways with hair cosmetic preparations. These include, for example, the cleansing of hair with shampoos, the care and regeneration with rinses and cures, and the bleaching, dyeing and shaping of the hair with colorants, tinting agents, waving agents and styling preparations. In this case, means for changing or nuancing the color of the head hair play a prominent role. As a result of this behavior, hair is exposed in many ways to straining influences that have a negative effect on the surface structure.
  • DE-C-197 09 334 discloses the use of proteolytically active enzymes for the enzymatic dissolution or detachment of the spread cuticular edges of the hair causing an undesired roughness of the hair surface.
  • the present invention therefore provides an agent for treating kera ⁇ tinischer fibers containing at least one protease and at least one further component which is selected from protein hydrolysates and vitamins, provitamins and vitamin precursors and their derivatives.
  • the above-explained combination treatment of the keratinic fibers with the agent according to the invention advantageously leads to an improvement in the damaged structure of the fibers.
  • the agent according to the invention for the treatment of keratinic fibers may contain one protease or else several mutually different proteases.
  • Proteases cleave peptide bonds within an amino acid chain. This can improve desquamation, increase pore size, and expose amino acid side chains. Thus, the penetration of the repair agents into the hair can be improved.
  • pro- and / or eukaryotic proteases can be used. Among other things, they differ in their gap specificity (specifically for specific amino acids in a chain or at random). For example, trypsin cleaves peptide bonds after the amino acids arginine and lysine. In this case, free amino groups are formed on the protein side chains, with which corresponding reactions are possible. The keratin structure is less strongly attacked than with the use of nonspecifically cleaving proteases such. bak ⁇ terieller subtilisins.
  • proteases can be used in the agent according to the invention, in particular the enzymes classified under EC 3.4 - Acting on peptide bonds (peptidases) which are available for example on the Internet under the URL http://www.chem.qmul.ac.Uk/iubmb / enzymes / EC3 / 4 / are listed.
  • Preferred proteases according to the invention are the serine endopeptidases (EC3.4.21) and the cysteine endopeptidases (EC3.4.22). Particularly preferred proteases according to the invention are selected from subtilisin ⁇ EC 3.4.21.62), papain ⁇ EC 3.4.22.2) and bromelain (EC 3.4.22.32).
  • the enzymes are preferably present in the agent according to the invention in amounts of from 0.005 to 10% by weight, based on the total preparation. Amounts of 0.01 to 5 wt .-% are particularly preferred.
  • the at least one further component is preferably present in the agent according to the invention in amounts of from 0.005 to 10% by weight, based on the total preparation. Amounts of 0.01 to 2 wt .-% are particularly preferred.
  • the agent according to the invention may comprise protein hydrolyzates, preferably cationized protein hydrolysates, wherein the protein hydrolyzate on which the animal is based, for example from collagen, milk or keratin, from the plant, for example from wheat, maize, rice, potatoes, soya or almonds, from marine life forms , for example from fish collagen or algae, or biotechnologically obtained protein hydrolysates.
  • the protein hydrolyzates on which the cationic derivatives according to the invention are based can be obtained from the corresponding proteins by chemical, in particular alkaline or acid hydrolysis, by enzymatic hydrolysis and / or a combination of both types of hydrolysis.
  • cationic protein hydrolyzates are understood to mean quaternized amino acids and mixtures thereof.
  • the quaternization of the protein hydrolyzates or of the amino acids is frequently carried out using quaternary ammonium salts such as, for example, N, N-dimethyl-N- (n-alkyl) -N- (2-hydroxy-3-chloro-n-propyl) -ammonium halides.
  • the cationic protein hydrolysates may also be further derivatized.
  • the cationic protein hydrolysates and derivatives are under the INCI - names in the "International Cosmetic Ingredient Dictionary and Handbook" (seventh edition 1997, The Cosmetic, letry TOI, and Fragrance Association 1101 17 th Street, NW, Suite 300, Washington, DC 20036-4702) Cocodimonium Hydroxypropyl Hydrolyzed Collagen, Cocodimopnium Hydroxypropyl Hydrolyzed Casein, Cocodimonium Hydroxypropyl Hydrolyzed Collagen, Cocodonium Hydroxypropyl Hydrolyzed Hair Keratin, Cocodimonium Hydroxypropyl Hydrolyzed Keratin, Cocodimonium Hydroxypropyl Hydrolyzed Rice Protein, Cocodimium Hydroxypropyl Hydrolyzed Silica, Cocodimonium Hydroxypropyl Hydrolyzed Soy Protein, Cocodimonium Hydroxypropyl Hydrolyzed Wheat Protein, Cocodimonium Hydr
  • the agent contains at least one cationic protein hydrolyzate.
  • the effect according to the invention can be increased still further if the agents of the present invention contain at least one cationic and at least one nonionic protein hydrolyzate.
  • the agents contain at least one wheat protein hydrolyzate.
  • agent according to the invention may contain vitamins, provitamins and vitamin precursor and their derivatives.
  • vitamins, pro-vitamins and vitamin precursors are preferred, which are usually assigned to groups A, B, C, E, F and H.
  • vitamin A includes retinol (vitamin Ai) and 3,4-didehydroretinol (vitamin A 2 ).
  • the ß-carotene is the provitamin of retinol.
  • vitamin A component according to the invention for example, vitamin A acid and its esters, vitamin A aldehyde and vitamin A alcohol and its esters such as the palmitate and the acetate into consideration.
  • the preparations used according to the invention preferably contain the vitamin A component in amounts of 0.05-1% by weight, based on the total preparation.
  • the vitamin B group or the vitamin B complex include - Vitamin Bi (thiamine) - Vitamin B2 (riboflavin)
  • nicotinic acid and nicotinic acid amide are frequently used under this name.
  • Preferred according to the invention is the nicotinic acid amide, which is contained in the agents used according to the invention preferably in amounts of from 0.05 to 1% by weight, based on the total agent.
  • panthenol and pantolactone pantothenic acid, panthenol and pantolactone.
  • panthenol and / or pantolactone Derivatives of panthenol which can be used according to the invention are in particular the esters and ethers of panthenol and also cationically derivatized panthenols. Individual representatives are, for example, the panthenol triacetate, the panthenol monoethyl ether and its monoacetate and also the cationic panthenol derivatives disclosed in WO 92/13829.
  • the said compounds of the vitamin B 5 type are contained in the agents used according to the invention preferably in amounts of 0.05-10% by weight, based on the total agent. Amounts of 0.1 to 5 wt .-% are particularly preferred.
  • Vitamin B ⁇ (pyridoxine and pyridoxamine and pyridoxal).
  • Vitamin C (ascorbic acid). Vitamin C is used in the compositions according to the invention preferably in amounts of 0.1 to 3 wt .-%, based on the total agent.
  • the use in the form of the palmitic acid ester, the glucosides or phosphates may be preferred.
  • the use in combination with tocopherols may also be preferred.
  • Vitamin E tocopherols, especially ⁇ -tocopherol.
  • Tocopherol and its derivatives which include in particular the esters such as acetate, nicotinate, phosphate and succinate, are preferably used in the compositions according to the invention in amounts of 0.05-1% by weight, based on the total agent , contain.
  • Vitamin F is usually understood as meaning essential fatty acids, in particular linoleic acid, linolenic acid and arachidonic acid.
  • Vitamin H is the compound (3aS, 4S, 6afi) -2-oxohexahydrothienol [3,4-c /] imidazole-4-valeric acid, for which, however, the trivial name biotin has meanwhile prevailed , Biotin is contained in the agents used according to the invention preferably in amounts of from 0.0001 to 1.0% by weight, in particular in amounts of from 0.001 to 0.01% by weight.
  • the agents used according to the invention preferably contain vitamins, provitamins and vitamin precursors from groups A, B, E and H.
  • Panthenol, pantolactone, pyridoxine and its derivatives as well as nicotinic acid amide and biotin are particularly preferred. Panthenol, pantolactone and nicotinic acid amide are very particularly preferred. Pantolactone has proven particularly suitable according to the invention.
  • the agent according to the invention contains at least one protein hydrolyzate and at least one vitamin, provitamin or a vitamin precursor and one of its derivatives.
  • pantolactone At least one cationic and at least one nonionic wheat protein hydrolyzate. This is beispiels ⁇ be achieved through the use of pantolactone in combination with the bottlesproduk ⁇ th Gluadin® ® WQ and Gluadin® ® WLM.
  • the use of the agent according to the invention is subject to no restrictions. It is in principle possible to apply two separate preparations comprising (a) the protease and (b) the at least one further component in succession in any order on the fibers. Here, however, between the steps (a) and (b) should not be too big time interval, so that the fibers do not dry between the steps.
  • the agent is preferably rinsed out after an exposure time of 1 minute to 60 hours. This rinsing can be carried out with pure water or a conventional shampoo. Exposure times of 5 to 15 minutes have proven sufficient in most cases.
  • composition of the invention at a temperature of 20 to 55 0 C, in particular of 35 to 40 0 C to apply.
  • compositions according to the invention are applied to the keratinic fiber, in particular human hair, there are no fundamental restrictions.
  • creams, solutions, solutions, waters, emulsions such as W / O, O / W, PIT emulsions (emulsions according to the teaching of phase inversion, PIT) are mentioned as the preparation of these preparations containing the agent according to the invention ), Microemulsions and multiple emulsions, gels, sprays, aerosols and foam aerosols.
  • alcoholic component used are lower alkanols and polyols such as propylene glycol and glycerol.
  • Ethanol and isopropanol are preferred alcohols.
  • Water and alcohol may be present in the aqueous alcoholic base in a weight ratio of 1:10 to 10: 1.
  • Water and aqueous-alcoholic mixtures which contain up to 50% by weight, in particular up to 25% by weight, of alcohol, based on the mixture of alcohol / water, may be preferred bases according to the invention.
  • the pH of these preparations may in principle be between 2 and 11. It is preferably between 2 and 7, with values of 3 to 5 being particularly preferred. To adjust this pH, virtually any acid or base that can be used for cosmetic purposes can be used.
  • acids are used as acids. applies.
  • By-acids are understood to mean those acids which are absorbed as part of the usual food intake and have positive effects on the human organism.
  • Eat acids are, for example, acetic acid, lactic acid, tartaric acid, citric acid, malic acid, ascorbic acid and gluconic acid.
  • citric acid and lactic acid is particularly preferred.
  • Preferred bases are ammonia, alkali hydroxides, triethanolamine and N, N, N ', N'-tetrakis (2-hydroxypropyl) ethylenediamine.
  • the agent can be confectioned as a single-chamber system or as a two-chamber system.
  • the enzyme component protease
  • the repair substance component protein hydrolysates, pantolactone, panthenol or niacinamide
  • a further subject of the present invention is a two-part kit for the treatment of keratinic fibers which is characterized in that it comprises a) the enzyme component (protease) and b) the repair substance component (protein hydrolysates, pantolactone, panthenol or niacinamide).
  • the agent may in principle contain all other components known to the person skilled in the art for such cosmetic compositions.
  • anionic surfactants in particular alkyl sulfates, alkyl polyglycol ether sulfates and ether carboxylic acids having 10 to 18 C atoms in the alkyl group and up to 12 glycol ether groups in the molecule, soaps and sulfosuccinic acid mono- and dialkyl esters having 8 to 18 C atoms in the alkyl group and sulfosuccinic acid.
  • soaps and sulfosuccinic acid mono- and dialkyl esters having 8 to 18 C atoms in the alkyl group and sulfosuccinic acid.
  • remono-alkylpolyoxyethyl esters having 8 to 18 C atoms in the alkyl group and 1 to 6 oxyethyl groups
  • ampholytic surfactants such as, for example, N-alkylglycines, N-alkylpropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each having about 8 to 18 C atoms in the alkyl group,
  • nonionic polymers such as vinyl pyrrolidone / vinyl acrylate copolymers, polyvinyl pyrrolidone and vinyl pyrrolidone / vinyl acetate copolymers and polysiloxanes,
  • Thickeners such as agar-agar, guar gum, alginates, xanthan gum, gum arabic, karaya gum, locust bean gum, linseed gums, dextrans, cellulose derivatives, e.g. For example, methylcellulose, hydroxyalkylcellulose and carboxymethylcellulose, starch fractions and derivatives such as amylose, amylopectin and dextrins, clays such.
  • B. bentonite or fully synthetic hydrocolloids such.
  • polyvinyl alcohol polyvinyl alcohol
  • hair-conditioning compounds such as phospholipids, for example soya lecithin, egg lecithin and cephalins, and also silicone oils,
  • Solvents and mediators such as ethanol, isopropanol, ethylene glycol, propylene glycol, glycerol and diethylene glycol,
  • dialkyl ethers having a total of from 12 to 36 carbon atoms, in particular 12 to 24 carbon atoms, such as di-n-octyl ether, di-n-decyl ether, di-n-nonyl ether, di-n undecyl ether and di-n-dodecyl ether, n-hexyl n-octyl ether, n-octyl n-decyl ether, n-decyl n-undecyl ether, n-undecyl n-dodecyl ether and n-hexyl n-undecyl ether, and di tert-butyl ether, di-iso-pentyl ether, di-3-ethyldecyl ether, tert-butyl-n-octyl ether, iso-
  • fiber-structure-improving active substances in particular mono-, di- and oligosaccharides, such as, for example, glucose, galactose, fructose, fructose and lactose,
  • paraffin oils such as paraffin oils, vegetable oils, eg. Sunflower oil, orange oil, almond oil, wheat germ oil and peach kernel oil and phospholipids, for example soya lecithin, egg lecithin and cephalins,
  • quaternized amines such as methyl-1-alkylamidoethyl-2-alkylimidazolinium methosulfate,
  • Anti-dandruff agents such as Piroctone Olamine, Zinc Omadine and Climbazole,
  • - light stabilizers in particular derivatized benzophenones, cinnamic acid derivatives and triazines,
  • Bodying agents such as sugar esters, polyol esters or polyol alkyl ethers,
  • - swelling and penetration substances such as glycerol, propylene glycol monoethyl ether, carbonates, bicarbonates, guanidines, ureas and primary, secondary and tertiary phosphates,
  • Opacifiers such as latex, styrene / PVP and styrene / acrylamide copolymers
  • Pearlescing agents such as ethylene glycol mono- and distearate and PEG-3-distearate,
  • - Reducing agents such as Thioglycolic acid and its derivatives, thiolactic acid, cysteamine, thiomalic acid and ⁇ -mercaptoethanesulfonic acid, Blowing agents such as propane-butane mixtures, N 2 O, dimethyl ether, CO 2 and air,
  • composition of the invention may also contain surfactants. These may be anionic, ampholytic, zwitterionic or nonionic surfactants as well as cationic surfactants.
  • surfactants may be anionic, ampholytic, zwitterionic or nonionic surfactants as well as cationic surfactants.
  • the person skilled in the art can optionally check a possible influence of the various surfactants on the activity of the protease by simple preliminary tests.
  • a combination of anionic and nonionic surfactants or a combination of anionic and amphoteric surfactants is used.
  • Suitable anionic surfactants in the compositions according to the invention are all anionic surfactants suitable for use on the human body. These are characterized by a water-solubilizing, anionic group such as. Example, a carboxylate, sulfate, sulfonate or phosphate group and a lipophilic alkyl group having about 10 to 22 carbon atoms. In addition, glycol or polyglycol ether groups, ester, ether and amide groups as well as hydroxyl groups can be contained in the molecule.
  • Nonionic surfactants contain as hydrophilic group z.
  • Such compounds are, for example
  • Preferred nonionic surfactants are alkyl polyglycosides of the general formula R 1 O- (Z) x . These compounds are characterized by the following parameters.
  • the alkyl radical R 1 contains 6 to 22 carbon atoms and may be both linear and branched. Preferred are primary linear and in the 2-position methylver ⁇ branched aliphatic radicals. Such alkyl radicals are, for example, 1-octyl, 1-decyl, 1-lauryl, 1-myristyl, 1-cetyl and 1-stearyl. Particularly preferred are 1-octyl, 1-decyl, 1-lauryl, 1-myristyl. When using so-called "oxo-alcohols" as starting materials, compounds with an odd number of carbon atoms in the alkyl chain predominate.
  • the alkyl polyglycosides which can be used according to the invention can contain, for example, only one particular alkyl radical R 1 .
  • these compounds are prepared starting from natural fats and oils or mineral oils.
  • the alkyl radicals R are mixtures corresponding to the starting compounds or corresponding to the particular work-up of these compounds.
  • R 1 consists essentially of Cs and C-io-alkyl groups, consisting essentially of C 12 - and C ⁇ alkyl groups, consisting essentially of C 8 - to C-i ⁇ -alkyl groups or substantially C 12 - to Ci 6 alkyl groups.
  • R 1 consists essentially of Cs and C-io-alkyl groups, consisting essentially of C 12 - and C ⁇ alkyl groups, consisting essentially of C 8 - to C-i ⁇ -alkyl groups or substantially C 12 - to Ci 6 alkyl groups.
  • Such sugars are, for example, glucose, fructose, galactose, arabinose, ribose, xylose, lyxose, allose, alto-rose, mannose, gulose, idose, talose and sucrose.
  • Preferred sugar building blocks are glucose, fructose, galactose, arabinose and sucrose; Glucose is particularly preferred.
  • alkyl polyglycosides which can be used according to the invention contain on average from 1.1 to 5 sugar units. Alkyl polyglycosides having x values of 1.1 to 1.6 are preferred. Very particular preference is given to alkyl glycosides in which x is 1: 1 to 1, 4.
  • the alkyl glycosides can also serve to improve the fixation of fragrance components on the hair.
  • this substance class as a further ingredient of the preparations according to the invention in the event that an effect of the perfume oil on the hair that extends beyond the duration of the hair treatment is desired.
  • alkoxylated homologs of said alkyl polyglycosides can also be used according to the invention. These homologs can contain on average up to 10 ethylene oxide and / or propylene oxide units per alkyl glycoside unit.
  • zwitterionic surfactants can be used, in particular as cosurfactants.
  • Zwitterionic surfactants are those surface-active compounds which carry at least one quaternary ammonium group and at least one -COO.sub.1 or -SOa.sub.2 group in the molecule.
  • Particularly suitable zwitterionic surfactants are the so-called betaines, such as the N-alkyl-N, N-dimethylammonium glycinates, for example the cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammoniumglyci- nate, for example the Kokosacylaminopropyl-dimethylammoniumglycinat, and 2-alkyl-3-carboxylmethyl-3-hydroxyethyl-imidazolines each having 8 to 18 C-men in the alkyl or acyl group and Kokosacylaminoethylhydroxyethyl- carboxymethylglycinat.
  • a preferred zwitterionic surfactant is the fatty acid amide derivative known by the INCI name Cocamidopropyl Betaine.
  • ampholytic surfactants are surface active compounds which, apart from a C 8 -C 8 alkyl or acyl group in the molecule min ⁇ least one free amino group and at least one -COOH or -SO 3 H group and capable of forming inner salts are.
  • ampholytic surfactants are N-alkylglycines, N-alkylpropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkyl-amidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each having about 8 to 18 C atoms in the alkyl group.
  • Particularly preferred ampholytic surfactants are N-cocoalkyl aminopropionate, cocoacylaminoethyl aminopropionate and C 12 - 18 - sarcosine.
  • the cationic surfactants used are, in particular, those of the quaternary ammonium compound type, the esterquats and the amidoamines.
  • Preferred quaternary ammonium compounds are ammonium halides, in particular chlorides and bromides, such as alkyltrimethylammonium chlorides, dialkyldimethylammonium chlorides and trialkylmethylammonium chlorides, eg. Cetyltrimethylammonium chloride, stearyltrimethylammonium chloride, distearyldimethylammonium chloride, lauryldimethylammonium chloride, lauryldimethylbenzylammonium chloride and tricetylmethylammonium chloride, as well as the imidazolium compounds known under the INCI names Quaternium-27 and Quaternium-83.
  • esterquats are known substances which contain both at least one ester function and at least one quaternary ammonium group as structural element.
  • Preferred esterquats are quaternized ester salts of fatty acids with triethanolamine, quaternized ester salts of fatty acids with diethanolalkylamines and quaternized ester salts of fatty acids with 1,2-dihydroxypropyldialkylamines.
  • Such products are marketed under the trade names Stepantex® ®, ® and Dehyquart® Armocare® ®.
  • the alkylamidoamines are usually prepared by amidation of natural or synthetic fatty acids and fatty acid cuts with dialkylaminoamines.
  • An inventively particularly suitable compound from this substance group Sub ⁇ presents under the name Tegoamid ® S 18 commercially exertli ⁇ che stearamidopropyl dimethylamine is.
  • the compounds used as surfactant with alkyl groups may each be uniform substances. However, it is generally preferred to use native vegetable or animal raw materials in the production of these substances, so that substance mixtures having different alkyl chain lengths depending on the respective raw material are obtained.
  • both products with a "normal” homolog distribution and those with a narrow homolog distribution can be used.
  • "normal” homolog distribution are meant mixtures of homologues which are obtained as catalysts in the reaction of fatty alcohol and alkylene oxide using alkali metals, alkali metal hydroxides or alkali metal alcoholates.
  • Narrow homolog distributions are obtained when For example, hydrotalcites, alkaline earth metal salts of ether carboxylic acids, alkaline earth metal oxides, hydroxides or alkoxides are used as catalysts. The use of products with narrow homolog distribution may be preferred.
  • Another object of the present invention is the use of at least one protease and at least one further component which is selected from protein hydrolysates and vitamins, provitamins and vitamin precursors and derivatives thereof for improving the structure keratini ⁇ shear fibers.
  • a further subject of the present invention is a process for improving the structure of keratinic fibers, characterized in that an agent according to the invention is applied to the keratinic fibers.
  • Pantolactone 0.5 Subtilisin or papain 0.5
  • Pantolactone 1 0 Subtilisin or papain 0.8
  • Pantolactone 0.5 Subtilisin or papain 0.2
  • Hair conditioner as in example 1, as 2-K system: 1st chamber:
  • the hair were before the zero measurement with a Texapon.RTM ® NSO - pre-purified solution (10% AS) and then permed standard. That is, 2 g of permanent wave gel (Poly-Lock 1) were distributed over 1 g of hair strand. Subsequently, after 40 minutes of exposure to the gel under standard conditions, it was rinsed with cold tap water for 60 seconds. This was followed by fixing with 2 g of Poly-Lock 2 per 1 g of hair strand over a period of 10 minutes.
  • a strand of hair was treated with an aqueous solution of the respective active ingredient mixture.
  • the immersion time was 15 minutes at room temperature.
  • the hair was then rinsed out for 30 seconds under cold, flowing water and air-dried. DSC measurements:
  • DSC measurements were performed.
  • the tresses were cut into small pieces ( ⁇ 1 mm) and then transferred to 5 aliquots of each strand of hair in the DSC measuring vessels. After adding aqua deion.
  • the measurements were carried out in a temperature range of 110-170 0 C, at 10 ° C / min.
  • the melting point (peak maximum in [ 0 C]) and the enthalpy of denaturation (area under the peak in [J / g]) were determined.
  • Ajidew ® NL50 sodium salt of pyrrolidone (substance content about 48-52% Aktiv ⁇ ; INCI name: Sodium PCA) (Ajino- moto)
  • Carbopol ® Polyarcylklare (INCI name: Carbomer) (Noveon) Cetiol ® HE Kokosmonglycerid with about 7.3 EO units (INCI name: PEG-7 glyceryl cocoate) (Cognis) Cremophor ® RH40 hydrogenated castor oil with 40-45 EO units (INCI name: PEG-40 Hydrogenated Castor Oil) (BASF) Cutina ® HR hydrogenated castor oil (INCI name: Hydrogenated Castor Oil) (Cognis) Dehyquart® ® A- CA trimethylhexadecylammonium chloride (about 24-26% active substance; INCI name: Aqua (Water), Cetrimonium Chloride) (Cognis)
  • Dehyquart ® F75 fatty alcohols Methyltriethanolammoniummethylsulfat--dialkyl-mixture (INCI name: Distearoylethyl Hydroxyethylmonium Methosulfate, Cetearyl Alcohol) (HENKEL)
  • Dow Corning ® 200 fluid polydimethylsiloxane (INCI designation: Dimethicone) (Dow Corning)
  • Dow Corning ® Q2-5220 silicone glycol copolymer (INCI name: dimethicone copolyol) (Dow Corning)
  • Eumulgin B2 ® cetylstearyl alcohol with about 20 EO units (INCI name: Ceteareth-20) (Cognis) Euperlan ® PK3000 about 60-64% solids; INCI name: Glycol Distearate, Glycerol, Laureth-4, Cocamidopropyl Betaine) (Cognis)
  • Gluadin ® WLM wheat protein hydrolyzate (about 21-24% solids, INCI name: Hydrolyzed Wheat Protein) (Cognis)
  • Gluadin ® WQ wheat protein hydrolyzate (about 31-35% solids, INCI name: Aqua (Water), Lauridimonium Hydroxypropyl Hydrolyzed Wheat Protein, Ethylparaben, Methylparaben) (Cognis)
  • Plantacare ® 818UP C8-14 alkyl polyglucoside (ca. 51-53% Akticsubstanzgehalt; INCI name: Coco-Glucoside, Aqua (Water)) (Cog nis) PVP / VA W-635 vinyl pyrrolidone vinyl acetate copolymer (Ca.48-52 % Fest ⁇ body in water; INCI name: VP / VA copolymer) (ISP) Rewoquat W75 ® l-methyl-2-nortalgalkyl-3-talgfett Anlagenreamidoethyl- imidazolinium methosulphate (75% active substance in production pylenglykol; INCI Name: Quaternium-27, Propylene Glycol) (WITCO)
  • Salcare ® SC 96 about 50% active ingredient content; INCI name: Polyquaternium-37, Propylene Glycol Dicaprylate / Dicaprate, PPG-1 Trideceth-6 (CIBA)

Abstract

The invention relates to an agent for treating keratin fibres, said agent containing at least one protease and at least one other constituent selected from protein hydrolysates, vitamins, provitamins and vitamin precursors, in addition to the derivatives thereof. The invention also relates to corresponding uses and methods for the treatment of keratin fibres.

Description

Neues Mittel zur Behandlung keratinischer FasernNew agent for the treatment of keratinic fibers
Die vorliegende Erfindung betrifft ein Mittel zur Behandlung keratinischer Fasern, das mindestens eine Protease und mindestens eine weitere Komponente enthält, die ausgewählt ist unter Proteinhydrolysaten sowie Vitaminen, Provitaminen und Vitaminvorstufen sowie deren Derivaten. Weiterhin betrifft die Erfindung entspre¬ chende Verwendungen sowie Verfahren zur Behandlung von keratinischen Fa¬ sern.The present invention relates to an agent for the treatment of keratinic fibers, which contains at least one protease and at least one further component which is selected from protein hydrolysates as well as vitamins, provitamins and vitamin precursors and derivatives thereof. Furthermore, the invention relates to corresponding uses and methods for the treatment of keratinic fibers.
Menschliches Haar wird heute in vielfältiger Weise mit haarkosmetischen Zube¬ reitungen behandelt. Dazu gehören etwa die Reinigung der Haare mit Shampoos, die Pflege und Regeneration mit Spülungen und Kuren sowie das Bleichen, Fär¬ ben und Verformen der Haare mit Färbemitteln, Tönungsmitteln, Wellmitteln und Stylingpräparaten. Dabei spielen Mittel zur Veränderung oder Nuancierung der Farbe des Kopfhaares eine herausragende Rolle. Dieses Verhalten führt dazu, dass Haare in vielfältiger Weise strapazierenden Einflüssen ausgesetzt sind, die sich negativ auf die Oberflächenstruktur auswirken.Human hair is today treated in a variety of ways with hair cosmetic preparations. These include, for example, the cleansing of hair with shampoos, the care and regeneration with rinses and cures, and the bleaching, dyeing and shaping of the hair with colorants, tinting agents, waving agents and styling preparations. In this case, means for changing or nuancing the color of the head hair play a prominent role. As a result of this behavior, hair is exposed in many ways to straining influences that have a negative effect on the surface structure.
Untersuchungen haben gezeigt, dass sich 70 Prozent der Frauen mehrmals pro Woche die Haare waschen, davon 8 Prozent täglich. Dieses Pflegeverhalten führt dazu, dass die sogenannten "Allzweck-Shampoos" durch vielfältige, bedürfnisge¬ rechte und schonendere Rezepturen abgelöst werden. Parallel dazu wächst ebenfalls der Bedarf an ergänzenden Pflegemitteln, denn mechanische Belas¬ tungen wie Kämmen, Fönen oder Reiben an der Kleidung strapazieren die Haa¬ re. Darüber hinaus wirken chemische Behandlungen wie z. B. Dauerwellen oder Farbveränderungen zusätzlich belastend. Ein Haar wird, bis es eine Länge von 20 cm erreicht hat, durchschnittlich 400 mal gewaschen, gefönt und gebürstet. Unter dem Mikroskop ist ungeschädigtes Haar vergleichbar mit einem Tannen¬ zapfen. Es ist von einer geschlossenen Schuppenschicht umgeben. Bei angegrif¬ fenem Haar ist diese Schicht nicht mehr geschlossen. Die Schuppen stehen ab und brechen teilweise heraus. Das darauffallende Licht wird nicht mehr reflektiert, die Haare wirken stumpf und glanzlos. Haarkuren mildern zwar schlimmere Prob¬ leme, machen das Haar aber oft "schwer" und wirken in vielen Fällen lediglich an der Oberfläche des Haares, so dass sie es folglich nicht komplett regenerieren können.Research has shown that 70 percent of women wash their hair several times a week, 8 percent a day. This care behavior means that the so-called "all-purpose shampoos" are replaced by a variety of needs-based and gentler formulations. At the same time, the need for supplementary care products is also growing, as mechanical stresses such as combing, blow-drying or rubbing on clothing strain the hair. In addition, chemical treatments such. B. perms or color changes in addition to stress. A hair is washed, blown and brushed on average 400 times until it reaches a length of 20 cm. Under the microscope, undamaged hair is comparable to a pine cone. It is surrounded by a closed scale layer. When attacked hair this layer is no longer closed. The scales are standing and break out partially. The incident light is no longer reflected, the hair looks dull and dull. Although hair treatments alleviate worse problems, they often make the hair "heavy" and, in many cases, only act on the surface of the hair so that they can not completely regenerate it.
Es hat daher nicht an Anstrengungen gefehlt, der Schädigung der Haarstruktur durch Einsatz von Pflegewirkstoffen entgegenzuwirken bzw. vorzubeugen. Es wurden vielfältige Pflegekomponenten entwickelt, die gezielt als Nachbehand¬ lungsmittel für geschädigtes Haar zum Einsatz kommen. Ferner wurden die Haarbehandlungsmittel an sich, wie beispielsweise die Fixiermittel im Rahmen einer Dauerwellbehandlung oder die Färbemittel, mit zusätzlichen Pflegestoffen versetzt. So wurde beispielsweise in der DE-A1-196 17 569 vorgeschlagen, spe¬ zielle Aminosäuren als Pflegestoffe zu verwenden.There has therefore been no lack of efforts to counteract or prevent the damage to the hair structure by using care ingredients. Various care components have been developed which are used specifically as aftertreatment agent for damaged hair. Further, the hair treatment agents per se, such as the fixer in the context of a permanent wave treatment or the colorants, added with additional care agents. For example, it has been proposed in DE-A1-196 17 569 to use special amino acids as care substances.
Die DE-C-197 09 334 offenbart den Einsatz proteolytisch aktiver Enzyme zur enzymatischen Auflösung oder Ablösung der eine unerwünschte Rauhigkeit der Haaroberfläche verursachenden abgespreizten Kutikularänder des Haares.DE-C-197 09 334 discloses the use of proteolytically active enzymes for the enzymatic dissolution or detachment of the spread cuticular edges of the hair causing an undesired roughness of the hair surface.
Es wurde nun überraschenderweise gefunden, dass der kombinierte Einsatz von proteolytisch aktiven Enzymen und Proteinhydrolysaten und/oder Vitaminen, Pro¬ vitaminen und Vitaminvorstufen sowie deren Derivaten bei keratinischen Fasern, insbesondere bei Haaren, einen beträchtlichen Repaireffekt bewirkt. Hierdurch wird der Zustand des Haares während der Haarbehandlung von innen her ver¬ bessert, indem die verwendeten Pflegestoffe in die zu behandelnden Haare ein¬ dringen. Dies führt zu einer Regenerierung bzw. Strukturstabilisierung der Haare, die nicht ausschließlich auf die Haaroberfläche beschränkt bleibt.It has now surprisingly been found that the combined use of proteolytically active enzymes and protein hydrolysates and / or vitamins, vitamins and vitamin precursors as well as their derivatives in keratinic fibers, in particular hair, causes a considerable repair effect. As a result, the condition of the hair during the hair treatment is improved from the inside by the fact that the care substances used penetrate into the hair to be treated. This leads to a regeneration or structure stabilization of the hair, which is not limited exclusively to the hair surface.
Gegenstand der vorliegenden Erfindung ist daher ein Mittel zur Behandlung kera¬ tinischer Fasern, das mindestens eine Protease und mindestens eine weitere Komponente enthält, die ausgewählt ist unter Proteinhydrolysaten sowie Vitami¬ nen, Provitaminen und Vitaminvorstufen sowie deren Derivaten. Die oben erläuterte Kombinationsbehandlung der keratinischen Fasern mit dem erfindungsgemäßen Mittel führt vorteilhafterweise zu einer Verbesserung der geschädigten Struktur der Fasern.The present invention therefore provides an agent for treating kera¬ tinischer fibers containing at least one protease and at least one further component which is selected from protein hydrolysates and vitamins, provitamins and vitamin precursors and their derivatives. The above-explained combination treatment of the keratinic fibers with the agent according to the invention advantageously leads to an improvement in the damaged structure of the fibers.
Das erfindungsgemäße Mittel zur Behandlung keratinischer Fasern kann eine Protease oder auch mehrere voneinander verschiedene Proteasen enthalten.The agent according to the invention for the treatment of keratinic fibers may contain one protease or else several mutually different proteases.
Proteasen spalten Peptid-Bindungen innerhalb einer Aminosäure-Kette. Dadurch kann die Abschuppung verbessert, Poren können vergrößert und Aminosäure- Seitenketten können freigelegt werden. Somit kann das Eindringen der Repair- wirkstoffe ins Haar verbessert werden.Proteases cleave peptide bonds within an amino acid chain. This can improve desquamation, increase pore size, and expose amino acid side chains. Thus, the penetration of the repair agents into the hair can be improved.
Es können erfindungsgemäß pro- und/oder eukaryotische Proteasen eingesetzt werden. Sie unterscheiden sich unter anderem durch ihre Spaltspezifität (gezielt nach bestimmten Aminosäuren in einer Kette oder zufällig). Beispielweise spaltet Trypsin Peptid-Bindungen nach den Aminosäuren Arginin und Lysin. Dabei ent¬ stehen freie Amino-Gruppen an den Protein-Seitenketten, mit denen entspre¬ chende Reaktionen möglich sind. Die Keratin-Struktur wird weniger stark ange¬ griffen als bei dem Einsatz von unspezifisch spaltenden Proteasen wie z.B. bak¬ terieller Subtilisine.According to the invention, pro- and / or eukaryotic proteases can be used. Among other things, they differ in their gap specificity (specifically for specific amino acids in a chain or at random). For example, trypsin cleaves peptide bonds after the amino acids arginine and lysine. In this case, free amino groups are formed on the protein side chains, with which corresponding reactions are possible. The keratin structure is less strongly attacked than with the use of nonspecifically cleaving proteases such. bak¬ terieller subtilisins.
In dem erfindungsgemäßen Mittel sind grundsätzlich alle Proteasen einsetzbar, insbesondere die unter EC 3.4 - Acting on peptide bonds (Peptidases) klassifi¬ zierten Enzyme, die beispielsweise im Internet unter der URL http://www.chem.qmul.ac.Uk/iubmb/enzyme/EC3/4/ aufgelistet sind.In principle, all proteases can be used in the agent according to the invention, in particular the enzymes classified under EC 3.4 - Acting on peptide bonds (peptidases) which are available for example on the Internet under the URL http://www.chem.qmul.ac.Uk/iubmb / enzymes / EC3 / 4 / are listed.
Bevorzugte Proteasen sind erfindungsgemäß die Serin Endopeptidasen (E.C.3.4.21) und die Cystein Endopeptidasen (E.C.3.4.22). Erfindungsgemäß besonders bevorzugte Proteasen sind ausgewählt unter Subti- lisin {EC 3.4.21.62), Papain {EC 3.4.22.2) und Bromelain (EC 3.4.22.32).Preferred proteases according to the invention are the serine endopeptidases (EC3.4.21) and the cysteine endopeptidases (EC3.4.22). Particularly preferred proteases according to the invention are selected from subtilisin {EC 3.4.21.62), papain {EC 3.4.22.2) and bromelain (EC 3.4.22.32).
Die Enzyme sind in dem erfindungsgemäßen Mittel bevorzugt in Mengen von 0,005 bis 10 Gew.-%, bezogen auf die gesamte Zubereitung, enthalten. Mengen von 0,01 bis 5 Gew.-% sind besonders bevorzugt.The enzymes are preferably present in the agent according to the invention in amounts of from 0.005 to 10% by weight, based on the total preparation. Amounts of 0.01 to 5 wt .-% are particularly preferred.
Die mindestens eine weitere Komponente ist in dem erfindungsgemäßen Mittel bevorzugt in Mengen von 0,005 bis 10 Gew.-%, bezogen auf die gesamte Zube¬ reitung, enthalten. Mengen von 0,01 bis 2 Gew.-% sind besonders bevorzugt.The at least one further component is preferably present in the agent according to the invention in amounts of from 0.005 to 10% by weight, based on the total preparation. Amounts of 0.01 to 2 wt .-% are particularly preferred.
Das erfindungsgemäße Mittel kann Proteinhydrolysate umfassen, vorzugsweise kationisierte Proteinhydrolysate, wobei das zugrunde liegende Proteinhydrolysat vom Tier, beispielsweise aus Collagen, Milch oder Keratin, von der Pflanze, bei¬ spielsweise aus Weizen, Mais, Reis, Kartoffeln, Soja oder Mandeln, von marinen Lebensformen, beispielsweise aus Fischcollagen oder Algen, oder biotechnolo¬ gisch gewonnenen Proteinhydrolysaten, stammen kann. Die den erfindungsge¬ mäßen kationischen Derivaten zugrunde liegenden Proteinhydrolysate können aus den entsprechenden Proteinen durch eine chemische, insbesondere alkali¬ sche oder saure Hydrolyse, durch eine enzymatische Hydrolyse und/oder einer Kombination aus beiden Hydrolysearten gewonnen werden. Die Hydrolyse von Proteinen ergibt in der Regel ein Proteinhydrolysat mit einer Molekulargewichts¬ verteilung von etwa 100 Dalton bis hin zu mehreren tausend Dalton. Bevorzugt sind solche kationischen Proteinhydrolysate, deren zugrunde liegender Protein¬ anteil ein Molekulargewicht von 100 bis zu 25000 Dalton, bevorzugt 250 bis 5000 Dalton aufweist. Weiterhin sind unter kationischen Proteinhydrolysaten quater- nierte Aminosäuren und deren Gemische zu verstehen. Die Quaternisierung der Proteinhydrolysate oder der Aminosäuren wird häufig mittels quarternären Am¬ moniumsalzen wie beispielsweise N,N-Dimethyl-N-(n-Alkyl)-N-(2-hydroxy-3- chloro-n-propyl)-ammoniumhalogeniden durchgeführt. Weiterhin können die kationischen Proteinhydrolysate auch noch weiter derivatisiert sein. Als typische Beispiele für die erfindungsgemäßen kationischen Proteinhydrolysate und - derivate seien die unter den INCI - Bezeichnungen im "International Cosmetic Ingredient Dictionary and Handbook", (seventh edition 1997, The Cosmetic, Toi- letry, and Fragrance Association 1101 17th Street, N.W., Suite 300, Washington, DC 20036-4702) genannten und im Handel erhältlichen Produkte genannt: Coco- dimonium Hydroxypropyl Hydrolyzed Collagen, Cocodimopnium Hydroxypropyl Hydrolyzed Casein, Cocodimonium Hydroxypropyl Hydrolyzed Collagen, Coco- dimonium Hydroxypropyl Hydrolyzed Hair Keratin, Cocodimonium Hydroxypropyl Hydrolyzed Keratin, Cocodimonium Hydroxypropyl Hydrolyzed Rice Protein, Cocodimonium Hydroxypropyl Hydrolyzed SiIk, Cocodimonium Hydroxypropyl Hydrolyzed Soy Protein, Cocodimonium Hydroxypropyl Hydrolyzed Wheat Prote¬ in, Cocodimonium Hydroxypropyl SiIk Amino Acids, Hydroxypropyl Arginine Lau- ryl/Myristyl Ether HCl, Hydroxypropyltrimonium Gelatin, Hydroxypropyltrimonium Hydrolyzed Casein, Hydroxypropyltrimonium Hydrolyzed Collagen, Hydroxypro¬ pyltrimonium Hydrolyzed Conchiolin Protein, Hydroxypropyltrimonium Hydrolyzed keratin, Hydroxypropyltrimonium Hydrolyzed Rice Bran Protein, Hydro- xyproypltrimonium Hydrolyzed SiIk, Hydroxypropyltrimonium Hydrolyzed Soy Protein, Hydroxypropyl Hydrolyzed Vegetable Protein, Hydroxypropyltrimonium Hydrolyzed Wheat Protein, Hydroxypropyltrimonium Hydrolyzed Wheat Prote- in/Siloxysilicate, Laurdimonium Hydroxypropyl Hydrolyzed Soy Protein, Laurdi- monium Hydroxypropyl Hydrolyzed Wheat Protein, Laurdimonium Hydroxypropyl Hydrolyzed Wheat Protein/Siloxysilicate, Lauryldimonium Hydroxypropyl Hydroly¬ zed Casein, Lauryldimonium Hydroxypropyl Hydrolyzed Collagen, Lauryldimoni¬ um Hydroxypropyl Hydrolyzed Keratin, Lauryldimonium Hydroxypropyl Hydroly¬ zed SiIk, Lauryldimonium Hydroxypropyl Hydrolyzed Soy Protein, Steardimonium Hydroxypropyl Hydrolyzed Casein, Steardimonium Hydroxypropyl Hydrolyzed Collagen, Steardimonium Hydroxypropyl Hydrolyzed Keratin, Steardimonium Hydroxypropyl Hydrolyzed Rice Protein, Steardimonium Hydroxypropyl Hydroly¬ zed SiIk, Steardimonium Hydroxypropyl Hydrolyzed Soy Protein, Steardimonium Hydroxypropyl Hydrolyzed Vegetable Protein, Steardimonium Hydroxypropyl Hydrolyzed Wheat Protein, Steartrimonium Hydroxyethyl Hydrolyzed Collagen, Quaternium-76 Hydrolyzed Collagen, Quaternium-79 Hydrolyzed Collagen, Qua- temium-79 Hydrolyzed Keratin, Quaternium-79 Hydrolyzed Milk Protein, Quater- nium-79 Hydrolyzed SiIk, Quatemium-79 Hydrolyzed Soy Protein, Quaternium-79 Hydrolyzed Wheat Protein. Ganz besonders bevorzugt sind die unter den Han¬ delsnamen Gluadin WQ und Gluadin WLM erhältlichen Proteinhydrolysate auf Weizenbasis.The agent according to the invention may comprise protein hydrolyzates, preferably cationized protein hydrolysates, wherein the protein hydrolyzate on which the animal is based, for example from collagen, milk or keratin, from the plant, for example from wheat, maize, rice, potatoes, soya or almonds, from marine life forms , for example from fish collagen or algae, or biotechnologically obtained protein hydrolysates. The protein hydrolyzates on which the cationic derivatives according to the invention are based can be obtained from the corresponding proteins by chemical, in particular alkaline or acid hydrolysis, by enzymatic hydrolysis and / or a combination of both types of hydrolysis. The hydrolysis of proteins usually results in a protein hydrolyzate having a molecular weight distribution of about 100 daltons up to several thousand daltons. Preference is given to those cationic protein hydrolyzates whose underlying protein content has a molecular weight of from 100 to 25,000 daltons, preferably from 250 to 5,000 daltons. Furthermore, cationic protein hydrolyzates are understood to mean quaternized amino acids and mixtures thereof. The quaternization of the protein hydrolyzates or of the amino acids is frequently carried out using quaternary ammonium salts such as, for example, N, N-dimethyl-N- (n-alkyl) -N- (2-hydroxy-3-chloro-n-propyl) -ammonium halides. Furthermore, the cationic protein hydrolysates may also be further derivatized. As typical examples of the cationic protein hydrolysates and derivatives are under the INCI - names in the "International Cosmetic Ingredient Dictionary and Handbook" (seventh edition 1997, The Cosmetic, letry TOI, and Fragrance Association 1101 17 th Street, NW, Suite 300, Washington, DC 20036-4702) Cocodimonium Hydroxypropyl Hydrolyzed Collagen, Cocodimopnium Hydroxypropyl Hydrolyzed Casein, Cocodimonium Hydroxypropyl Hydrolyzed Collagen, Cocodonium Hydroxypropyl Hydrolyzed Hair Keratin, Cocodimonium Hydroxypropyl Hydrolyzed Keratin, Cocodimonium Hydroxypropyl Hydrolyzed Rice Protein, Cocodimium Hydroxypropyl Hydrolyzed Silica, Cocodimonium Hydroxypropyl Hydrolyzed Soy Protein, Cocodimonium Hydroxypropyl Hydrolyzed Wheat Protein, Cocodimonium Hydroxypropyl SiCl Amino Acids, Hydroxypropyl Arginine Lauryl / Myristyl Ether HCl, Hydroxypropyltrimonium Gelatin, Hydroxypropyltrimonium Hydrolyzed Casein, Hydroxypropyltrimonium Hydrolyzed Collagen, Hydroxypropyltrimonium Hydr olyzed Conchiolin Protein, Hydroxypropyltrimonium Hydrolyzed Keratin, Hydroxypropyltrimonium Hydrolyzed Rice Bran Protein, Hydroxypropylpltrimonium Hydrolyzed Silicon, Hydroxypropyltrimonium Hydrolyzed Soy Protein, Hydroxypropyl Hydrolyzed Vegetable Protein, Hydroxypropyltrimonium Hydrolyzed Wheat Protein, Hydroxypropyltrimonium Hydrolyzed Wheat Protein / Siloxysilicate, Laurdimonium Hydroxypropyl Hydrolyzed Soy Protein, Lauridonium Hydroxypropyl Hydrolyzed Wheat Protein, Laurodimonium Hydroxypropyl Hydrolyzed Wheat Protein / Siloxysilicate, Lauryldimony Hydroxypropyl Hydrolyzed Casein, Lauryldimony Hydroxypropyl Hydrolyzed Collagen, Lauryldimonium Hydroxypropyl Hydrolyzed Keratin, Lauryldimony Hydroxypropyl Hydrolyzed Silicon, Lauryldimonium Hydroxypropyl Hydrolyzed Soy Protein, Steardimonium Hydroxypropyl Hydrolyzed Casein, Steardimonium Hydroxypropyl Hydrolyzed Collagen, Steardimonium Hydroxypropyl Hydrolyzed Keratin, Steardimonium Hydroxypropyl Hydrolyzed Rice Protein, Ste Ardimony Hydroxypropyl Hydrolyzed Sickle, Steardimonium Hydroxypropyl Hydrolyzed Soy Protein, Steardimonium Hydroxypropyl Hydrolyzed Vegetable Protein, Steardimonium Hydroxypropyl Hydrolyzed Wheat Protein, Steartrimonium Hydroxyethyl Hydrolyzed Collagen, Quaternium-76 Hydrolyzed Collagen, Quaternium-79 Hydrolyzed Collagen, Quaternium-79 Hydrolyzed Keratin, Quaternium-79 Hydrolyzed Milk Protein, Quaternary nium-79 Hydrolyzed Sick, Quaternium-79 Hydrolyzed Soy Protein, Quaternium-79 Hydrolyzed Wheat Protein. Very particular preference is given to the protein hydrolyzates based on wheat which are available under the trade names Gluadin WQ and Gluadin WLM.
Es hat sich erfindungsgemäß als bevorzugte erwiesen, wenn das Mittel mindes¬ tens ein kationisches Proteinhydrolysat enthält. Dabei kann die erfindungsgemä¬ ße Wirkung noch weiter gesteigert werden, wenn die Mittel der vorliegenden Erfindung mindestens ein kationisches sowie mindestens ein nichtionisches Pro¬ teinhydrolysat enthalten.It has proved to be preferred according to the invention if the agent contains at least one cationic protein hydrolyzate. In this case, the effect according to the invention can be increased still further if the agents of the present invention contain at least one cationic and at least one nonionic protein hydrolyzate.
Weiterhin hat es sich erfindungsgemäß als bevorzugt erwiesen, wenn die Mittel mindestens ein Weizenproteinhydrolysat enthalten.Furthermore, it has proved to be preferred according to the invention if the agents contain at least one wheat protein hydrolyzate.
Weiterhin kann das erfindungsgemäße Mittel Vitamine, Provitamine und Vitamin¬ vorstufe sowie deren Derivate enthalten.Furthermore, the agent according to the invention may contain vitamins, provitamins and vitamin precursor and their derivatives.
Dabei sind erfindungsgemäß solche Vitamine, Pro-Vitamine und Vitaminvorstufen bevorzugt, die üblicherweise den Gruppen A, B, C, E, F und H zugeordnet wer¬ den.According to the invention, such vitamins, pro-vitamins and vitamin precursors are preferred, which are usually assigned to groups A, B, C, E, F and H.
Zur Gruppe der als Vitamin A bezeichneten Substanzen gehören das Retinol (Vitamin Ai) sowie das 3,4-Didehydroretinol (Vitamin A2). Das ß-Carotin ist das Provitamin des Retinols. Als Vitamin A-Komponente kommen erfindungsgemäß beispielsweise Vitamin A-Säure und deren Ester, Vitamin A-Aldehyd und Vitamin A-Alkohol sowie dessen Ester wie das Palmitat und das Acetat in Betracht. Die erfindungsgemäß verwendeten Zubereitungen enthalten die Vitamin A- Komponente bevorzugt in Mengen von 0,05-1 Gew.-%, bezogen auf die gesamte Zubereitung.The group of substances called vitamin A includes retinol (vitamin Ai) and 3,4-didehydroretinol (vitamin A 2 ). The ß-carotene is the provitamin of retinol. As vitamin A component according to the invention, for example, vitamin A acid and its esters, vitamin A aldehyde and vitamin A alcohol and its esters such as the palmitate and the acetate into consideration. The preparations used according to the invention preferably contain the vitamin A component in amounts of 0.05-1% by weight, based on the total preparation.
Zur Vitamin B-Gruppe oder zu dem Vitamin B-Komplex gehören u. a. - Vitamin Bi (Thiamin) - Vitamin B2 (Riboflavin)The vitamin B group or the vitamin B complex include - Vitamin Bi (thiamine) - Vitamin B2 (riboflavin)
- Vitamin B3. Unter dieser Bezeichnung werden häufig die Verbindungen Ni- cotinsäure und Nicotinsäureamid (Niacinamid) geführt. Erfindungsgemäß bevorzugt ist das Nicotinsäureamid, das in den erfindungsgemäß verwen- detenen Mitteln bevorzugt in Mengen von 0,05 bis 1 Gew.-%, bezogen auf das gesamte Mittel, enthalten ist.- Vitamin B3. The compounds nicotinic acid and nicotinic acid amide (niacinamide) are frequently used under this name. Preferred according to the invention is the nicotinic acid amide, which is contained in the agents used according to the invention preferably in amounts of from 0.05 to 1% by weight, based on the total agent.
- Vitamin B5 (Pantothensäure, Panthenol und Pantolacton). Im Rahmen die¬ ser Gruppe wird bevorzugt das Panthenol und/oder Pantolacton einge¬ setzt. Erfindungsgemäß einsetzbare Derivate des Panthenols sind insbe¬ sondere die Ester und Ether des Panthenols sowie kationisch derivatisierte Panthenole. Einzelne Vertreter sind beispielsweise das Panthenoltriacetat, der Panthenolmonoethylether und dessen Monoacetat sowie die in der WO 92/13829 offenbarten kationischen Panthenolderivate. Die genannten Verbindungen des Vitamin B5-Typs sind in den erfindungsgemäß verwen¬ deten Mitteln bevorzugt in Mengen von 0,05 - 10 Gew.-%, bezogen auf das gesamte Mittel, enthalten. Mengen von 0,1 - 5 Gew.-% sind beson¬ ders bevorzugt.- Vitamin B 5 (pantothenic acid, panthenol and pantolactone). In the context of this group it is preferred to use the panthenol and / or pantolactone. Derivatives of panthenol which can be used according to the invention are in particular the esters and ethers of panthenol and also cationically derivatized panthenols. Individual representatives are, for example, the panthenol triacetate, the panthenol monoethyl ether and its monoacetate and also the cationic panthenol derivatives disclosed in WO 92/13829. The said compounds of the vitamin B 5 type are contained in the agents used according to the invention preferably in amounts of 0.05-10% by weight, based on the total agent. Amounts of 0.1 to 5 wt .-% are particularly preferred.
- Vitamin Bβ (Pyridoxin sowie Pyridoxamin und Pyridoxal).- Vitamin Bβ (pyridoxine and pyridoxamine and pyridoxal).
Vitamin C (Ascorbinsäure). Vitamin C wird in den erfindungsgemäß verwendeten Mitteln bevorzugt in Mengen von 0,1 bis 3 Gew.-%, bezogen auf das gesamte Mittel eingesetzt. Die Verwendung in Form des Palmitinsäureesters, der Glucosi- de oder Phosphate kann bevorzugt sein. Die Verwendung in Kombination mit Tocopherolen kann ebenfalls bevorzugt sein.Vitamin C (ascorbic acid). Vitamin C is used in the compositions according to the invention preferably in amounts of 0.1 to 3 wt .-%, based on the total agent. The use in the form of the palmitic acid ester, the glucosides or phosphates may be preferred. The use in combination with tocopherols may also be preferred.
Vitamin E (Tocopherole, insbesondere α-Tocopherol). Tocopherol und seine Derivate, worunter insbesondere die Ester wie das Acetat, das Nicotinat, das Phosphat und das Succinat fallen, sind in den erfindungsgemäß verwendeten Mitteln bevorzugt in Mengen von 0,05-1 Gew.-%, bezogen auf das gesamte Mit¬ tel, enthalten.Vitamin E (tocopherols, especially α-tocopherol). Tocopherol and its derivatives, which include in particular the esters such as acetate, nicotinate, phosphate and succinate, are preferably used in the compositions according to the invention in amounts of 0.05-1% by weight, based on the total agent , contain.
Vitamin F. Unter dem Begriff "Vitamin F" werden üblicherweise essentielle Fett¬ säuren, insbesondere Linolsäure, Linolensäure und Arachidonsäure, verstanden. Vitamin H. Als Vitamin H wird die Verbindung (3aS,4S, 6afi)-2-Oxohexahy- drothienol[3,4-c/]-imidazol-4-valeriansäure bezeichnet, für die sich aber inzwi¬ schen der Trivialname Biotin durchgesetzt hat. Biotin ist in den erfindungsgemäß verwendeten Mitteln bevorzugt in Mengen von 0,0001 bis 1 ,0 Gew.-%, insbeson¬ dere in Mengen von 0,001 bis 0,01 Gew.-% enthalten.Vitamin F. The term "vitamin F" is usually understood as meaning essential fatty acids, in particular linoleic acid, linolenic acid and arachidonic acid. Vitamin H. The vitamin H is the compound (3aS, 4S, 6afi) -2-oxohexahydrothienol [3,4-c /] imidazole-4-valeric acid, for which, however, the trivial name biotin has meanwhile prevailed , Biotin is contained in the agents used according to the invention preferably in amounts of from 0.0001 to 1.0% by weight, in particular in amounts of from 0.001 to 0.01% by weight.
Bevorzugt enthalten die erfindungsgemäß verwendeten Mittel Vitamine, Provita¬ mine und Vitaminvorstufen aus den Gruppen A, B, E und H.The agents used according to the invention preferably contain vitamins, provitamins and vitamin precursors from groups A, B, E and H.
Panthenol, Pantolacton, Pyridoxin und seine Derivate sowie Nicotinsäureamid und Biotin sind besonders bevorzugt. Panthenol, Pantolacton sowie Nicotinsäu¬ reamid sind ganz besonders bevorzugt. Als ganz besonders geeignet hat sich erfindungsgemäß Pantolacton erwiesen.Panthenol, pantolactone, pyridoxine and its derivatives as well as nicotinic acid amide and biotin are particularly preferred. Panthenol, pantolactone and nicotinic acid amide are very particularly preferred. Pantolactone has proven particularly suitable according to the invention.
Im Rahmen einer besonders bevorzugte Ausführungsform der vorliegenden Er¬ findung enthält das erfindungsgemäße Mittel mindestens ein Proteinhydrolysat und mindestens ein Vitamin, Provitamin oder eine Vitaminvorstufe sowie eines deren Derivate enthält.Within the scope of a particularly preferred embodiment of the present invention, the agent according to the invention contains at least one protein hydrolyzate and at least one vitamin, provitamin or a vitamin precursor and one of its derivatives.
Ganz besonders bevorzugt im Sinne der vorliegenden Erfindung ist die eine Wirkstoff kombination aus Pantolacton, mindestens einem kationischen sowie mindestens einem nichtionischen Weizenproteinhydrolysat. Dies wird beispiels¬ weise durch den Einsatz von Pantolacton in Kombination mit den Handelsproduk¬ ten Gluadin® WQ und Gluadin® WLM erreicht.Very particularly preferred for the purposes of the present invention is an active ingredient combination of pantolactone, at least one cationic and at least one nonionic wheat protein hydrolyzate. This is beispiels¬ be achieved through the use of pantolactone in combination with the Handelsproduk¬ th Gluadin® ® WQ and Gluadin® ® WLM.
Hinsichtlich des zeitlichen Ablaufs unterliegt der Einsatz des erfindungsgemäßen Mittels keinerlei Beschränkungen. Es ist prinzipiell möglich, zwei separate Zube¬ reitungen, enthaltend (a) die Protease und (b) die mindestens eine weitere Kom¬ ponente nacheinander in beliebiger Reihenfolge auf die Fasern aufzubringen. Hierbei sollte allerdings zwischen den Schritten (a) und (b) kein allzu großer zeitlicher Abstand liegen, so dass die Fasern zwischen den Schritten nicht trock¬ nen.With regard to the time schedule, the use of the agent according to the invention is subject to no restrictions. It is in principle possible to apply two separate preparations comprising (a) the protease and (b) the at least one further component in succession in any order on the fibers. Here, however, between the steps (a) and (b) should not be too big time interval, so that the fibers do not dry between the steps.
Obwohl das erfindungsgemäße Mittel prinzipiell auf dem Haar verbleiben kann, wird das Mittel vorzugsweise nach einer Einwirkzeit von 1 Minute bis 60 Stunden ausgespült. Dieses Ausspülen kann mit reinem Wasser oder einem marktübli¬ chen Shampoo erfolgen. Einwirkzeiten von 5 bis 15 Minuten haben sich in den meisten Fällen als ausreichend erwiesen.Although the composition according to the invention can in principle remain on the hair, the agent is preferably rinsed out after an exposure time of 1 minute to 60 hours. This rinsing can be carried out with pure water or a conventional shampoo. Exposure times of 5 to 15 minutes have proven sufficient in most cases.
Unabhängig von dem genauen Ablauf der Vorbehandlung hat es sich als vorteil¬ haft erwiesen, das erfindungsgemäße Mittel bei einer Temperatur von 20 bis 55 0C, insbesondere von 35 bis 400C, anzuwenden.Regardless of the exact sequence of the pretreatment, it has proved to be vorteil¬ way, composition of the invention at a temperature of 20 to 55 0 C, in particular of 35 to 40 0 C to apply.
Hinsichtlich der Art, gemäß das erfindungsgemäße Mittel auf die keratinische Faser, insbesondere das menschliche Haar, aufgebracht wird, bestehen keine prinzipiellen Einschränkungen. Als Konfektionierung dieser das das erfindungs¬ gemäße Mittel enthaltenden Zubereitungen sind beispielsweise Cremes, Lo¬ tionen, Lösungen, Wässer, Emulsionen wie W/O-, O/W-, PIT-Emulsionen (Emul¬ sionen nach der Lehre der Phaseninversion, PIT genannt), Mikroemulsionen und multiple Emulsionen, Gele, Sprays, Aerosole und Schaumaerosole geeignet. Diese werden in der Regel auf wäßriger oder wäßrig-alkoholischer Basis formu¬ liert. Als alkoholische Komponente kommen dabei niedere Alkanole sowie Polyo- Ie wie Propylenglykol und Glycerin zum Einsatz. Ethanol und Isopropanol sind bevorzugte Alkohole. Wasser und Alkohol können in der wäßrig alkoholischen Basis in einem Gewichtsverhältnis von 1 : 10 bis 10 : 1 vorliegen. Wasser sowie wäßrig-alkoholische Mischungen, die bis zu 50 Gew.-%, insbesondere bis zu 25 Gew.-%, Alkohol, bezogen auf das Gemisch Alkohol/Wasser, enthalten, können erfindungsgemäß bevorzugte Grundlagen sein. Der pH-Wert dieser Zubereitun¬ gen kann prinzipiell bei Werten von 2 - 11 liegen. Er liegt bevorzugt zwischen 2 und 7, wobei Werte von 3 bis 5 besonders bevorzugt sind. Zur Einstellung dieses pH-Wertes kann praktisch jede für kosmetische Zwecke verwendbare Säure oder Base verwendet werden. Üblicherweise werden als Säuren Genußsäuren ver- wendet. Unter Genußsäuren werden solche Säuren verstanden, die im Rahmen der üblichen Nahrungsaufnahme aufgenommen werden und positive Auswirkun¬ gen auf den menschlichen Organismus haben. Genußsäuren sind beispielsweise Essigsäure, Milchsäure, Weinsäure, Zitronensäure, Äpfelsäure, Ascorbinsäure und Gluconsäure. Im Rahmen der Erfindung ist die Verwendung von Zitronen¬ säure und Milchsäure besonders bevorzugt. Bevorzugte Basen sind Ammoniak, Alkalihydroxide, Triethanolamin sowie N,N,N',N'-Tetrakis-(2-hydroxypropyl)- ethylendiamin.With regard to the way in which the composition according to the invention is applied to the keratinic fiber, in particular human hair, there are no fundamental restrictions. For example, creams, solutions, solutions, waters, emulsions such as W / O, O / W, PIT emulsions (emulsions according to the teaching of phase inversion, PIT) are mentioned as the preparation of these preparations containing the agent according to the invention ), Microemulsions and multiple emulsions, gels, sprays, aerosols and foam aerosols. These are usually formu lated on an aqueous or aqueous-alcoholic basis. The alcoholic component used are lower alkanols and polyols such as propylene glycol and glycerol. Ethanol and isopropanol are preferred alcohols. Water and alcohol may be present in the aqueous alcoholic base in a weight ratio of 1:10 to 10: 1. Water and aqueous-alcoholic mixtures which contain up to 50% by weight, in particular up to 25% by weight, of alcohol, based on the mixture of alcohol / water, may be preferred bases according to the invention. The pH of these preparations may in principle be between 2 and 11. It is preferably between 2 and 7, with values of 3 to 5 being particularly preferred. To adjust this pH, virtually any acid or base that can be used for cosmetic purposes can be used. Usually acids are used as acids. applies. By-acids are understood to mean those acids which are absorbed as part of the usual food intake and have positive effects on the human organism. Eat acids are, for example, acetic acid, lactic acid, tartaric acid, citric acid, malic acid, ascorbic acid and gluconic acid. In the context of the invention, the use of citric acid and lactic acid is particularly preferred. Preferred bases are ammonia, alkali hydroxides, triethanolamine and N, N, N ', N'-tetrakis (2-hydroxypropyl) ethylenediamine.
Das Mittel kann als Einkammersystem oder als Zweikammersystem konfektio¬ niert werden. Bei einem Zweikammersystem sind typischerweise die Enzymkom¬ ponente (Protease) und die Repairstoffkomponente (Proteinhydrolisate, Pantolac- ton, Panthenol oder Niacinamid) räumlich voneinander getrennt.The agent can be confectioned as a single-chamber system or as a two-chamber system. In a two-chamber system, typically the enzyme component (protease) and the repair substance component (protein hydrolysates, pantolactone, panthenol or niacinamide) are spatially separated from one another.
Ein weiterer Gegenstand der vorliegenden Erfindung ist ein zweiteiliges Kit zur Behandlung keratinischer Fasern, das dadurch gekennzeichnet ist, dass es a) die Enzymkomponente (Protease) und b) die Repairstoffkomponente (Proteinhydrolisate, Pantolacton, Panthenol oder Niacinamid) umfasst.A further subject of the present invention is a two-part kit for the treatment of keratinic fibers which is characterized in that it comprises a) the enzyme component (protease) and b) the repair substance component (protein hydrolysates, pantolactone, panthenol or niacinamide).
Neben dem erfindungsgemäß zwingend erforderlichen Enzym und der mindes¬ tens einen weiteren oben genannten Komponente, kann das Mittel prinzipiell alle weiteren, dem Fachmann für solche kosmetischen Mittel bekannten Kompo¬ nenten enthalten.In addition to the enzyme which is absolutely necessary according to the invention and the at least one further component mentioned above, the agent may in principle contain all other components known to the person skilled in the art for such cosmetic compositions.
Weitere Wirk-, Hilfs- und Zusatzstoffe sind beispielsweiseOther active ingredients, auxiliaries and additives are, for example
- anionische Tenside, insbesondere Alkylsulfate, Alkylpolyglykolethersulfate und Ethercarbonsäuren mit 10 bis 18 C-Atomen in der Alkylgruppe und bis zu 12 Glykolethergruppen im Molekül, Seifen sowie Sulfobernsteinsäuremono- und -dialkylester mit 8 bis 18 C-Atomen in der Alkylgruppe und Sulfobernsteinsäu- remono-alkylpolyoxyethyl-ester mit 8 bis 18 C-Atomen in der Alkylgruppe und 1 bis 6 Oxyethylgruppen,anionic surfactants, in particular alkyl sulfates, alkyl polyglycol ether sulfates and ether carboxylic acids having 10 to 18 C atoms in the alkyl group and up to 12 glycol ether groups in the molecule, soaps and sulfosuccinic acid mono- and dialkyl esters having 8 to 18 C atoms in the alkyl group and sulfosuccinic acid. remono-alkylpolyoxyethyl esters having 8 to 18 C atoms in the alkyl group and 1 to 6 oxyethyl groups,
- ampholytische Tenside wie beispielsweise N-Alkylglycine, N-Alkylpropion- säuren, N-Alkylaminobuttersäuren, N-Alkyliminodipropionsäuren, N-Hydroxy- ethyl-N-alkylamidopropylglycine, N-Alkyltaurine, N-Alkylsarcosine, 2-Alkyl- aminopropionsäuren und Alkyl-aminoessigsäuren mit jeweils etwa 8 bis 18 C- Atomen in der Alkylgruppe,ampholytic surfactants such as, for example, N-alkylglycines, N-alkylpropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each having about 8 to 18 C atoms in the alkyl group,
- nichtionische Polymere wie beispielsweise Vinylpyrrolidon/Vinylacrylat- Copolymere, Polyvinylpyrrolidon und Vinylpyrrolidon/Vinylacetat-Copolymere und Polysiloxane,nonionic polymers such as vinyl pyrrolidone / vinyl acrylate copolymers, polyvinyl pyrrolidone and vinyl pyrrolidone / vinyl acetate copolymers and polysiloxanes,
- Verdickungsmittel wie Agar-Agar, Guar-Gum, Alginate, Xanthan-Gum, Gummi arabicum, Karaya-Gummi, Johannisbrotkernmehl, Leinsamengummen, Dextrane, Cellulose-Derivate, z. B. Methylcellulose, Hydroxyalkylcellulose und Carboxymethylcellulose, Stärke-Fraktionen und Derivate wie Amylose, Amy- lopektin und Dextrine, Tone wie z. B. Bentonit oder vollsynthetische Hydrokol- loide wie z. B. Polyvinylalkohol,Thickeners such as agar-agar, guar gum, alginates, xanthan gum, gum arabic, karaya gum, locust bean gum, linseed gums, dextrans, cellulose derivatives, e.g. For example, methylcellulose, hydroxyalkylcellulose and carboxymethylcellulose, starch fractions and derivatives such as amylose, amylopectin and dextrins, clays such. B. bentonite or fully synthetic hydrocolloids such. For example, polyvinyl alcohol,
- Strukturanten wie Maleinsäure und Milchsäure,- structurants such as maleic acid and lactic acid,
- haarkonditionierende Verbindungen wie Phospholipide, beispielsweise Sojaleci- thin, Ei-Lecitin und Kephaline, sowie Silikonöle,hair-conditioning compounds such as phospholipids, for example soya lecithin, egg lecithin and cephalins, and also silicone oils,
- Parfümöle, Dimethylisosorbid und Cyclodextrine,Perfume oils, dimethylisosorbide and cyclodextrins,
- Lösungsmittel und -vermittler wie Ethanol, Isopropanol, Ethylenglykol, Propylen- glykol, Glycerin und Diethylenglykol,Solvents and mediators such as ethanol, isopropanol, ethylene glycol, propylene glycol, glycerol and diethylene glycol,
- symmetrische und unsymmetrische, lineare und verzweigte Dialkylether mit insgesamt zwischen 12 bis 36 C-Atomen, insbesondere 12 bis 24 C-Atomen, wie beispielsweise Di-n-octylether, Di-n-decylether, Di-n-nonylether, Di-n- undecylether und Di-n-dodecylether, n-Hexyl-n-octylether, n-Octyl-n- decylether, n-Decyl-n-undecylether, n-Undecyl-n-dodecylether und n-Hexyl-n- Undecylether sowie Di-tert-butylether, Di-iso-pentylether, Di-3-ethyldecylether, tert.-Butyl-n-octylether, iso-Pentyl-n-octylether und 2-Methyl-pentyl-n- octylether, - Fettalkohole, insbesondere lineare und/oder gesättigte Fettalkohole mit 8 bis 30- symmetrical and unsymmetrical, linear and branched dialkyl ethers having a total of from 12 to 36 carbon atoms, in particular 12 to 24 carbon atoms, such as di-n-octyl ether, di-n-decyl ether, di-n-nonyl ether, di-n undecyl ether and di-n-dodecyl ether, n-hexyl n-octyl ether, n-octyl n-decyl ether, n-decyl n-undecyl ether, n-undecyl n-dodecyl ether and n-hexyl n-undecyl ether, and di tert-butyl ether, di-iso-pentyl ether, di-3-ethyldecyl ether, tert-butyl-n-octyl ether, iso-pentyl-n-octyl ether and 2-methyl-pentyl-n-octyl ether, Fatty alcohols, especially linear and / or saturated fatty alcohols with 8 to 30
C-Atomen, und Monoester der Fettsäuren mit Alkoholen mit 6 bis 24 C- Atomen,C atoms, and monoesters of fatty acids with alcohols having 6 to 24 carbon atoms,
- faserstrukturverbessernde Wirkstoffe, insbesondere Mono-, Di- und Oligosac¬ charide, wie beispielsweise Glucose, Galactose, Fructose, Fruchtzucker und Lactose,fiber-structure-improving active substances, in particular mono-, di- and oligosaccharides, such as, for example, glucose, galactose, fructose, fructose and lactose,
- konditionierende Wirkstoffe wie Paraffinöle, pflanzliche Öle, z. B. Sonnenblu¬ menöl, Orangenöl, Mandelöl, Weizenkeimöl und Pfirsichkernöl sowie Phospholipide, beispielsweise Sojalecithin, Ei-Lecithin und Kephaline,- Conditioning agents such as paraffin oils, vegetable oils, eg. Sunflower oil, orange oil, almond oil, wheat germ oil and peach kernel oil and phospholipids, for example soya lecithin, egg lecithin and cephalins,
- quatemierte Amine wie Methyl-1-alkylamidoethyl-2-alkylimidazolinium-me- thosulfat,quaternized amines such as methyl-1-alkylamidoethyl-2-alkylimidazolinium methosulfate,
- Entschäumer wie Silikone,Defoamers like silicones,
- Farbstoffe zum Anfärben des Mittels,Dyes for staining the agent,
- Antischuppenwirkstoffe wie Piroctone Olamine, Zink Omadine und Climbazol,Anti-dandruff agents such as Piroctone Olamine, Zinc Omadine and Climbazole,
- Lichtschutzmittel, insbesondere derivatisierte Benzophenone, Zimtsäure- Derivate und Triazine,- light stabilizers, in particular derivatized benzophenones, cinnamic acid derivatives and triazines,
- weitere Substanzen zur Einstellung des pH-Wertes, wie beispielsweise α- und ß-Hydroxycarbonsäuren- Other substances for adjusting the pH, such as α- and ß-hydroxycarboxylic acids
- Wirkstoffe wie Allantoin und Bisabolol,- active substances such as allantoin and bisabolol,
- Cholesterin,- cholesterol,
- Konsistenzgeber wie Zuckerester, Polyolester oder Polyolalkylether,Bodying agents such as sugar esters, polyol esters or polyol alkyl ethers,
- Fette und Wachse wie Walrat, Bienenwachs, Montanwachs und Paraffine,- fats and waxes such as spermaceti, beeswax, montan wax and paraffins,
- Fettsäurealkanolamide,Fatty acid alkanolamides,
- Komplexbildner wie EDTA, NTA, ß-Alanindiessigsäure und Phosphonsäuren,Complexing agents such as EDTA, NTA, β-alaninediacetic acid and phosphonic acids,
- Quell- und Penetrationsstoffe wie Glycerin, Propylenglykolmonoethylether, Carbonate, Hydrogencarbonate, Guanidine, Harnstoffe sowie primäre, sekun¬ däre und tertiäre Phosphate,- swelling and penetration substances such as glycerol, propylene glycol monoethyl ether, carbonates, bicarbonates, guanidines, ureas and primary, secondary and tertiary phosphates,
- Trübungsmittel wie Latex, Styrol/PVP- und Styrol/Acrylamid-CopolymereOpacifiers such as latex, styrene / PVP and styrene / acrylamide copolymers
- Perlglanzmittel wie Ethylenglykolmono- und -distearat sowie PEG-3-distearat,Pearlescing agents such as ethylene glycol mono- and distearate and PEG-3-distearate,
- Pigmente,- pigments,
- Reduktionsmittel wie z. B. Thioglykolsäure und deren Derivate, Thio- milchsäure, Cysteamin, Thioäpfelsäure und α-Mercaptoethansulfonsäure, - Treibmittel wie Propan-Butan-Gemische, N2O, Dimethylether, CO2 und Luft,- Reducing agents such. Thioglycolic acid and its derivatives, thiolactic acid, cysteamine, thiomalic acid and α-mercaptoethanesulfonic acid, Blowing agents such as propane-butane mixtures, N 2 O, dimethyl ether, CO 2 and air,
- Antioxidantien.- antioxidants.
Das erfindungsgemäße Mittel kann außerdem Tenside enthalten. Bei diesen kann es sich sowohl um anionische, ampholytische, zwitterionische oder nichtio- nogene Tenside als auch um kationische Tenside handeln. Der Fachmann kann einen eventuellen Einfluß der verschiedenen Tenside auf die Aktivität der Protea¬ se gegebenenfalls durch einfache Vorversuche überprüfen.The composition of the invention may also contain surfactants. These may be anionic, ampholytic, zwitterionic or nonionic surfactants as well as cationic surfactants. The person skilled in the art can optionally check a possible influence of the various surfactants on the activity of the protease by simple preliminary tests.
In einer bevorzugten Ausführungsform der vorliegenden Erfindung wird eine Kombination aus anionischen und nichtionischen Tensiden oder eine Kombinati¬ on aus anionischen und amphoteren Tensiden eingesetzt.In a preferred embodiment of the present invention, a combination of anionic and nonionic surfactants or a combination of anionic and amphoteric surfactants is used.
Es hat sich aber in Einzelfällen als vorteilhaft erwiesen, die Tenside aus ampho¬ teren oder nichtionischen Tensiden auszuwählen.However, it has proven advantageous in individual cases to select the surfactants from ampho¬ teren or nonionic surfactants.
Als anionische Tenside eignen sich in erfindungsgemäßen Mitteln alle für die Ver¬ wendung am menschlichen Körper geeigneten anionischen oberflächenaktiven Stoffe. Diese sind gekennzeichnet durch eine wasserlöslich machende, anioni¬ sche Gruppe wie z. B. eine Carboxylat-, Sulfat-, Sulfonat- oder Phosphat-Gruppe und eine lipophile Alkylgruppe mit etwa 10 bis 22 C-Atomen. Zusätzlich können im Molekül Glykol- oder Polyglykolether-Gruppen, Ester-, Ether- und Amidgrup- pen sowie Hydroxylgruppen enthalten sein.Suitable anionic surfactants in the compositions according to the invention are all anionic surfactants suitable for use on the human body. These are characterized by a water-solubilizing, anionic group such as. Example, a carboxylate, sulfate, sulfonate or phosphate group and a lipophilic alkyl group having about 10 to 22 carbon atoms. In addition, glycol or polyglycol ether groups, ester, ether and amide groups as well as hydroxyl groups can be contained in the molecule.
Nichtionogene Tenside enthalten als hydrophile Gruppe z. B. eine Polyolgruppe, eine Polyalkylenglykolethergruppe oder eine Kombination aus Polyol- und PoIy- glykolethergruppe. Solche Verbindungen sind beispielsweiseNonionic surfactants contain as hydrophilic group z. A polyol group, a polyalkylene glycol ether group or a combination of polyol and polyglycol ether groups. Such compounds are, for example
Anlagerungsprodukte von 2 bis 30 Mol Ethylenoxid und/oder 0 bis 5 Mol Propylenoxid an lineare Fettalkohole mit 8 bis 22 C-Atomen, an Fettsäuren mit 12 bis 22 C-Atomen und an Alkylphenole mit 8 bis 15 C-Atomen in der Alkylgruppe, Ci2-C-22-Fettsäuremono- und -diester von Anlagerungsprodukten von 1 bis 30 Mol Ethylenoxid an Glycerin,Addition products of 2 to 30 moles of ethylene oxide and / or 0 to 5 moles of propylene oxide to linear fatty alcohols having 8 to 22 carbon atoms, to fatty acids having 12 to 22 carbon atoms and to alkylphenols having 8 to 15 carbon atoms in the alkyl group, C 2 -C 22 -fatty acid mono- and diesters of addition products of 1 to 30 mol of ethylene oxide with glycerol,
C8-C22-Alkylmono- und -oligoglycoside und deren ethoxylierte Analoga sowie Anlagerungsprodukte von 5 bis 60 Mol Ethylenoxid an Rizinusöl und ge¬ härtetes Rizinusöl.C 8 -C 22 -Alkylmono- and oligoglycosides and their ethoxylated analogs and addition products of 5 to 60 moles of ethylene oxide with castor oil and hardened castor oil.
Bevorzugte nichtionische Tenside sind Alkylpolyglykoside der allgemeinen For¬ mel R1O-(Z)x. Diese Verbindungen sind durch die folgenden Parameter gekenn¬ zeichnet.Preferred nonionic surfactants are alkyl polyglycosides of the general formula R 1 O- (Z) x . These compounds are characterized by the following parameters.
Der Alkylrest R1 enthält 6 bis 22 Kohlenstoffatome und kann sowohl linear als auch verzweigt sein. Bevorzugt sind primäre lineare und in 2-Stellung methylver¬ zweigte aliphatische Reste. Solche Alkylreste sind beispielsweise 1-Octyl, 1-De- cyl, 1-Lauryl, 1-Myristyl, 1-Cetyl und 1-Stearyl. Besonders bevorzugt sind 1-Octyl, 1-Decyl, 1-Lauryl, 1-Myristyl. Bei Verwendung sogenannter "Oxo-Alkohole" als Ausgangsstoffe überwiegen Verbindungen mit einer ungeraden Anzahl von Koh¬ lenstoffatomen in der Alkylkette.The alkyl radical R 1 contains 6 to 22 carbon atoms and may be both linear and branched. Preferred are primary linear and in the 2-position methylver¬ branched aliphatic radicals. Such alkyl radicals are, for example, 1-octyl, 1-decyl, 1-lauryl, 1-myristyl, 1-cetyl and 1-stearyl. Particularly preferred are 1-octyl, 1-decyl, 1-lauryl, 1-myristyl. When using so-called "oxo-alcohols" as starting materials, compounds with an odd number of carbon atoms in the alkyl chain predominate.
Die erfindungsgemäß verwendbaren Alkylpolyglykoside können beispielsweise nur einen bestimmten Alkylrest R1 enthalten. Üblicherweise werden diese Verbin¬ dungen aber ausgehend von natürlichen Fetten und Ölen oder Mineralölen her¬ gestellt. In diesem Fall liegen als Alkylreste R Mischungen entsprechend den Ausgangsverbindungen bzw. entsprechend der jeweiligen Aufarbeitung dieser Verbindungen vor.The alkyl polyglycosides which can be used according to the invention can contain, for example, only one particular alkyl radical R 1 . Usually, however, these compounds are prepared starting from natural fats and oils or mineral oils. In this case, the alkyl radicals R are mixtures corresponding to the starting compounds or corresponding to the particular work-up of these compounds.
Besonders bevorzugt sind solche Alkylpolyglykoside, bei denen R1 im wesentlichen aus Cs- und C-io-Alkylgruppen, im wesentlichen aus C12- und C^-Alkylgruppen, im wesentlichen aus C8- bis C-iβ-Alkylgruppen oder im wesentlichen aus C12- bis Ci6-Alkylgruppen besteht. Als Zuckerbaustein Z können beliebige Mono- oder Oligosaccharide eingesetzt werden. Üblicherweise werden Zucker mit 5 bzw. 6 Kohlenstoffatomen sowie die entsprechenden Oligosaccharide eingesetzt. Solche Zucker sind beispielsweise Glucose, Fructose, Galactose, Arabinose, Ribose, Xylose, Lyxose, Allose, Alt¬ rose, Mannose, Gulose, Idose, Talose und Sucrose. Bevorzugte Zuckerbausteine sind Glucose, Fructose, Galactose, Arabinose und Sucrose; Glucose ist beson¬ ders bevorzugt.Particularly preferred are those alkyl polyglycosides in which R 1 consists essentially of Cs and C-io-alkyl groups, consisting essentially of C 12 - and C ^ alkyl groups, consisting essentially of C 8 - to C-iβ-alkyl groups or substantially C 12 - to Ci 6 alkyl groups. As sugar building block Z it is possible to use any desired mono- or oligosaccharides. Usually, sugars with 5 or 6 carbon atoms and the corresponding oligosaccharides are used. Such sugars are, for example, glucose, fructose, galactose, arabinose, ribose, xylose, lyxose, allose, alto-rose, mannose, gulose, idose, talose and sucrose. Preferred sugar building blocks are glucose, fructose, galactose, arabinose and sucrose; Glucose is particularly preferred.
Die erfindungsgemäß verwendbaren Alkylpolyglykoside enthalten im Schnitt 1 ,1 bis 5 Zuckereinheiten. Alkylpolyglykoside mit x-Werten von 1 ,1 bis 1 ,6 sind be¬ vorzugt. Ganz besonders bevorzugt sind Alkylglykoside, bei denen x 1 ,1 bis 1 ,4 beträgt.The alkyl polyglycosides which can be used according to the invention contain on average from 1.1 to 5 sugar units. Alkyl polyglycosides having x values of 1.1 to 1.6 are preferred. Very particular preference is given to alkyl glycosides in which x is 1: 1 to 1, 4.
Die Alkylglykoside können neben ihrer Tensidwirkung auch dazu dienen, die Fixierung von Duftkomponenten auf dem Haar zu verbessern. Der Fachmann wird also für den Fall, dass eine über die Dauer der Haarbehandlung hinausge¬ hende Wirkung des Parfümöles auf dem Haar gewünscht wird, bevorzugt zu dieser Substanzklasse als weiterem Inhaltsstoff der erfindungsgemäßen Zuberei¬ tungen zurückgreifen.In addition to their surfactant action, the alkyl glycosides can also serve to improve the fixation of fragrance components on the hair. The person skilled in the art will therefore prefer to use this substance class as a further ingredient of the preparations according to the invention in the event that an effect of the perfume oil on the hair that extends beyond the duration of the hair treatment is desired.
Auch die alkoxylierten Homologen der genannten Alkylpolyglykoside können er¬ findungsgemäß eingesetzt werden. Diese Homologen können durchschnittlich bis zu 10 Ethylenoxid- und/oder Propylenoxideinheiten pro Alkylglykosideinheit ent¬ halten.The alkoxylated homologs of said alkyl polyglycosides can also be used according to the invention. These homologs can contain on average up to 10 ethylene oxide and / or propylene oxide units per alkyl glycoside unit.
Weiterhin können, insbesondere als Co-Tenside, zwitterionische Tenside ver¬ wendet werden. Als zwitterionische Tenside werden solche oberflächenaktive Verbindungen bezeichnet, die im Molekül mindestens eine quartäre Ammonium¬ gruppe und mindestens eine -COO^- oder -SOa^-Gruppe tragen. Besonders geeignete zwitterionische Tenside sind die sogenannten Betaine wie die N-Alkyl- N,N-dimethylammonium-glycinate, beispielsweise das Kokosalkyl-di- methylammonium-glycinat, N-Acyl-aminopropyl-N,N-dimethylammoniumglyci- nate, beispielsweise das Kokosacylaminopropyl-dimethylammoniumglycinat, und 2-Alkyl-3-carboxylmethyl-3-hydroxyethyl-imidazoline mit jeweils 8 bis 18 C-Ato- men in der Alkyl- oder Acylgruppe sowie das Kokosacylaminoethylhydroxyethyl- carboxymethylglycinat. Ein bevorzugtes zwitterionisches Tensid ist das unter der INCI-Bezeichnung Cocamidopropyl Betaine bekannte Fettsäureamid-Derivat.Furthermore, zwitterionic surfactants can be used, in particular as cosurfactants. Zwitterionic surfactants are those surface-active compounds which carry at least one quaternary ammonium group and at least one -COO.sub.1 or -SOa.sub.2 group in the molecule. Particularly suitable zwitterionic surfactants are the so-called betaines, such as the N-alkyl-N, N-dimethylammonium glycinates, for example the cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammoniumglyci- nate, for example the Kokosacylaminopropyl-dimethylammoniumglycinat, and 2-alkyl-3-carboxylmethyl-3-hydroxyethyl-imidazolines each having 8 to 18 C-men in the alkyl or acyl group and Kokosacylaminoethylhydroxyethyl- carboxymethylglycinat. A preferred zwitterionic surfactant is the fatty acid amide derivative known by the INCI name Cocamidopropyl Betaine.
Ebenfalls insbesondere als Co-Tenside geeignet sind ampholytische Tenside. Unter ampholytischen Tensiden werden solche oberflächenaktiven Verbindungen verstanden, die außer einer C8-C-i8-Alkyl- oder Acylgruppe im Molekül min¬ destens eine freie Aminogruppe und mindestens eine -COOH- oder -SO3H- Gruppe enthalten und zur Ausbildung innerer Salze befähigt sind. Beispiele für geeignete ampholytische Tenside sind N-Alkylglycine, N-Alkylpropionsäuren, N- Alkylaminobuttersäuren, N-Alkyliminodipropionsäuren, N-Hydroxyethyl-N-alkyl- amidopropylglycine, N-Alkyltaurine, N-Alkylsarcosine, 2-Alkylaminopropionsäuren und Alkylaminoessigsäuren mit jeweils etwa 8 bis 18 C-Atomen in der Al- kylgruppe. Besonders bevorzugte ampholytische Tenside sind das N-Kokosalkyl- aminopropionat, das Kokosacylaminoethylaminopropionat und das C12-18- Acylsarcosin.Also particularly suitable as co-surfactants are ampholytic surfactants. Ampholytic surfactants are surface active compounds which, apart from a C 8 -C 8 alkyl or acyl group in the molecule min¬ least one free amino group and at least one -COOH or -SO 3 H group and capable of forming inner salts are. Examples of suitable ampholytic surfactants are N-alkylglycines, N-alkylpropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkyl-amidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each having about 8 to 18 C atoms in the alkyl group. Particularly preferred ampholytic surfactants are N-cocoalkyl aminopropionate, cocoacylaminoethyl aminopropionate and C 12 - 18 - sarcosine.
Erfindungsgemäß werden als kationische Tenside insbesondere solche vom Typ der quartären Ammoniumverbindungen, der Esterquats und der Amidoamine eingesetzt.According to the invention, the cationic surfactants used are, in particular, those of the quaternary ammonium compound type, the esterquats and the amidoamines.
Bevorzugte quaternäre Ammoniumverbindungen sind Ammoniumhalogenide, insbesondere Chloride und Bromide, wie Alkyltrimethylammoniumchloride, Dial- kyldimethylammoniumchloride und Trialkylmethylammoniumchloride, z. B. Ce- tyltrimethylammoniumchlorid, Stearyltrimethylammoniumchlorid, Distea- ryldimethylammoniumchlorid, Lauryldimethylammoniumchlorid, Lauryl- dimethylbenzylammoniumchlorid und Tricetylmethylammoniumchlorid, sowie die unter den INCI-Bezeichnungen Quaternium-27 und Quatemium-83 bekannten Imidazolium-Verbindungen. Die langen Alkylketten der oben genannten Tenside weisen bevorzugt 10 bis 18 Kohlenstoffatome auf. Bei Esterquats handelt es sich um bekannte Stoffe, die sowohl mindestens eine Esterfunktion als auch mindestens eine quartäre Ammoniumgruppe als Struktur¬ element enthalten. Bevorzugte Esterquats sind quaternierte Estersalze von Fett¬ säuren mit Triethanolamin, quaternierte Estersalze von Fettsäuren mit Diethano- lalkylaminen und quatemierten Estersalze von Fettsäuren mit 1 ,2- Dihydroxypropyldialkylaminen. Solche Produkte werden beispielsweise unter den Warenzeichen Stepantex®, Dehyquart® und Armocare® vertrieben. Die Produkte Armocare® VGH-70, ein N,N-Bis(2-Palmitoyloxyethyl)dimethylammoniumchlorid, sowie Dehyquart® F-75 und Dehyquart® AU-35 sind Beispiele für solche Ester¬ quats.Preferred quaternary ammonium compounds are ammonium halides, in particular chlorides and bromides, such as alkyltrimethylammonium chlorides, dialkyldimethylammonium chlorides and trialkylmethylammonium chlorides, eg. Cetyltrimethylammonium chloride, stearyltrimethylammonium chloride, distearyldimethylammonium chloride, lauryldimethylammonium chloride, lauryldimethylbenzylammonium chloride and tricetylmethylammonium chloride, as well as the imidazolium compounds known under the INCI names Quaternium-27 and Quaternium-83. The long alkyl chains of the above-mentioned surfactants preferably have 10 to 18 carbon atoms. Esterquats are known substances which contain both at least one ester function and at least one quaternary ammonium group as structural element. Preferred esterquats are quaternized ester salts of fatty acids with triethanolamine, quaternized ester salts of fatty acids with diethanolalkylamines and quaternized ester salts of fatty acids with 1,2-dihydroxypropyldialkylamines. Such products are marketed under the trade names Stepantex® ®, ® and Dehyquart® Armocare® ®. The products Armocare ® VGH-70, a N, N-bis (2-palmitoyloxyethyl) dimethylammonium chloride, as well as Dehyquart ® F-75 and Dehyquart ® AU-35 are examples of such ester-quats.
Die Alkylamidoamine werden üblicherweise durch Amidierung natürlicher oder synthetischer Fettsäuren und Fettsäureschnitte mit Dialkylaminoaminen herge¬ stellt. Eine erfindungsgemäß besonders geeignete Verbindung aus dieser Sub¬ stanzgruppe stellt das unter der Bezeichnung Tegoamid® S 18 im Handel erhältli¬ che Stearamidopropyl-dimethylamin dar.The alkylamidoamines are usually prepared by amidation of natural or synthetic fatty acids and fatty acid cuts with dialkylaminoamines. An inventively particularly suitable compound from this substance group Sub¬ presents under the name Tegoamid ® S 18 commercially erhältli¬ che stearamidopropyl dimethylamine is.
Bei den als Tensid eingesetzten Verbindungen mit Alkylgruppen kann es sich jeweils um einheitliche Substanzen handeln. Es ist jedoch in der Regel bevor¬ zugt, bei der Herstellung dieser Stoffe von nativen pflanzlichen oder tierischen Rohstoffen auszugehen, so dass man Substanzgemische mit unterschiedlichen, vom jeweiligen Rohstoff abhängigen Alkylkettenlängen erhält.The compounds used as surfactant with alkyl groups may each be uniform substances. However, it is generally preferred to use native vegetable or animal raw materials in the production of these substances, so that substance mixtures having different alkyl chain lengths depending on the respective raw material are obtained.
Bei den Tensiden, die Anlagerungsprodukte von Ethylen- und/oder Propylenoxid an Fettalkohole oder Derivate dieser Anlagerungsprodukte darstellen, können sowohl Produkte mit einer "normalen" Homologenverteilung als auch solche mit einer eingeengten Homologenverteilung verwendet werden. Unter "normaler" Homologenverteilung werden dabei Mischungen von Homologen verstanden, die man bei der Umsetzung von Fettalkohol und Alkylenoxid unter Verwendung von Alkalimetallen, Alkalimetallhydroxiden oder Alkalimetallalkoholaten als Katalysa¬ toren erhält. Eingeengte Homologenverteilungen werden dagegen erhalten, wenn beispielsweise Hydrotalcite, Erdalkalimetallsalze von Ethercarbonsäuren, Erdal¬ kalimetalloxide, -hydroxide oder -alkoholate als Katalysatoren verwendet werden. Die Verwendung von Produkten mit eingeengter Homologenverteilung kann be¬ vorzugt sein.In the case of the surfactants which are adducts of ethylene oxide and / or propylene oxide with fatty alcohols or derivatives of these addition products, both products with a "normal" homolog distribution and those with a narrow homolog distribution can be used. By "normal" homolog distribution are meant mixtures of homologues which are obtained as catalysts in the reaction of fatty alcohol and alkylene oxide using alkali metals, alkali metal hydroxides or alkali metal alcoholates. Narrow homolog distributions are obtained when For example, hydrotalcites, alkaline earth metal salts of ether carboxylic acids, alkaline earth metal oxides, hydroxides or alkoxides are used as catalysts. The use of products with narrow homolog distribution may be preferred.
Bezüglich weiterer fakultativer Komponenten sowie die eingesetzten Mengen dieser Komponenten wird ausdrücklich auf die dem Fachmann bekannten ein¬ schlägigen Handbücher, z. B. Kh. Schrader, Grundlagen und Rezepturen der Kosmetika, 2. Auflage, Hüthig Buch Verlag, Heidelberg, 1989, verwiesen.With regard to further optional components and the amounts of these components used, reference is expressly made to the relevant manuals known to the person skilled in the art, eg. B. Kh. Schrader, bases and formulations of cosmetics, 2nd edition, Hüthig book publisher, Heidelberg, 1989, referenced.
Ein weiterer Gegenstand der vorliegenden Erfindung ist die Verwendung von mindestens einer Protease und mindestens einer weiteren Komponente, die ausgewählt ist unter Proteinhydrolysaten sowie Vitaminen, Provitaminen und Vitaminvorstufen sowie deren Derivaten zur Verbesserung der Struktur keratini¬ scher Fasern.Another object of the present invention is the use of at least one protease and at least one further component which is selected from protein hydrolysates and vitamins, provitamins and vitamin precursors and derivatives thereof for improving the structure keratini¬ shear fibers.
Ein weiterer Gegenstand der vorliegenden Erfindung ist ein Verfahren zur Ver¬ besserung der Struktur keratinischer Fasern, dadurch gekennzeichnet, dass man ein erfindungsgemäßes Mittel auf die keratinischen Fasern aufbringt. A further subject of the present invention is a process for improving the structure of keratinic fibers, characterized in that an agent according to the invention is applied to the keratinic fibers.
Die folgenden Beispiele erläutern die Erfindung, ohne sie jedoch darauf einzu¬ schränken:The following examples illustrate the invention without, however, restricting it to:
Beispiel 1:Example 1:
Haarspülunghair conditioner
Eumulgin® B2 0,3Eumulgin ® B2 0.3
Cetyl/Stearylalkohol 3,3Cetyl / stearyl alcohol 3,3
Isopropylmyristat 0,5Isopropyl myristate 0.5
Paraffmöl perliquidum 15 cSt. DAB 9 0,3Paraffin oil perliquidum 15 cSt. DAB 9 0.3
Dehyquart®A-CA 2,0Dehyquart® ® A-CA 2.0
Gluadin® WQ 0,2Gluadin WQ ® 0.2
Gluadin® WLM 0,5Gluadin ® WLM 0.5
Pantolacton 0,5Pantolactone 0.5
Subtilisin oder Papain 0,5Subtilisin or papain 0.5
Phenonip® 0,8Phenonip ® 0.8
Wasser ad 100 pH = 7,0Water ad 100 pH = 7.0
Beispiel 2:Example 2:
Haarspülunghair conditioner
Eumulgin® B2 0,3Eumulgin ® B2 0.3
Cetyl/Stearylalkohol 3,3Cetyl / stearyl alcohol 3,3
Isopropylmyristat 0,5Isopropyl myristate 0.5
Paraffinöl perliquidum 15 cSt. DAB 9 0,3Paraffin oil perliquidum 15 cSt. DAB 9 0.3
Dehyquart®L 80 2,0Dehyquart ® L 80 2.0
Gluadin® WQ 0,5Gluadin WQ ® 0.5
Gluadin® WLM 0,2Gluadin ® WLM 0.2
Pantolacton 1 ,0Pantolactone 1, 0
Subtilisin oder Papain 1 ,0Subtilisin or papain 1, 0
Citronensäure 0,4 Phenonip® 0,8Citric acid 0.4 Phenonip ® 0.8
Wasser ad 100 pH 7,0Water ad 100 pH 7.0
Beispiel 3:Example 3:
Haarkur (rinse off)Hair Conditioner (rinse off)
Dehyquart® F75 4,0Dehyquart ® F75 4.0
Cetyl/Stearylalkohol 4,0Cetyl / stearyl alcohol 4.0
Paraffmöl perliquidum 15 cSt. DAB 9 1 ,5Paraffin oil perliquidum 15 cSt. DAB 9 1, 5
Dehyquart® A-CA 4,0Dehyquart® ® A-CA 4.0
Salcare®SC 96 0,5Salcare ® SC 96 0.5
Gluadin®WQ 1 ,0Gluadin® ® WQ 1, 0
Gluadin® WLM 1 ,0Gluadin® ® WLM 1, 0
Pantolacton 0,5Pantolactone 0.5
Subtilisin oder Papain 0,2Subtilisin or papain 0.2
Citronensäure 0,15Citric acid 0.15
Phenonip® 0,8Phenonip ® 0.8
Wasser ad 100 pH = 7,0Water ad 100 pH = 7.0
Beispiel 4:Example 4:
Haarkur (rinse off)Hair Conditioner (rinse off)
Dehyquart® L80 4,0Dehyquart ® L80 4.0
Cetyl/Stearylalkohol 6,0Cetyl / stearyl alcohol 6.0
Paraffmöl perliquidum 15 cSt. DAB 9 2,0Paraffin oil perliquidum 15 cSt. DAB 9 2.0
Rewoquat®W 75 2,0Rewoquat ® W 75 2.0
Sepigel®305 0,5Sepigel ® 305 0.5
Gluadin® WQ 0,2Gluadin WQ ® 0.2
Gluadin® WLM 0,5Gluadin ® WLM 0.5
Pantolacton 0,5 Subtilisin oder Papain 0,5Pantolactone 0.5 Subtilisin or papain 0.5
Citronensäure 0,15Citric acid 0.15
Phenonip® 0,8Phenonip ® 0.8
Wasser ad 100 pH = 7,0Water ad 100 pH = 7.0
Beispiel 5:Example 5:
Haarkur (auf dem Haar verbleibend)Hair cure (remaining on the hair)
Dehyquart® F75 0,3Dehyquart ® F75 0.3
Salcare®SC 96 5,0Salcare ® SC 96 5.0
Dow Corning®200 Fluid, 5 cSt. 1 ,5Dow Corning® 200 Fluid, 5 cSt. 1, 5
Gafquat®755N 1 ,5Gafquat ® 755N 1, 5
Biodocarb® 0,8Biodocarb ® 0.8
Gluadin® WQ 0,2Gluadin WQ ® 0.2
Gluadin® WLM 0,5Gluadin ® WLM 0.5
Pantolacton 0,5Pantolactone 0.5
Subtilisin oder Papain 0,5Subtilisin or papain 0.5
Parfumöl 0,25Perfume oil 0.25
Wasser ad 100 pH = 7,0Water ad 100 pH = 7.0
Beispiel 6:Example 6:
Haarkur (auf dem Haar verbleibend)Hair cure (remaining on the hair)
Sepigel®305 5,0Sepigel ® 305 5.0
Dow Coming®Q2-5220 5 cSt. 1 ,5Dow Coming ® Q2-5220 5 cSt. 1, 5
Genamin®DSAC 0,3Genamin DSAC ® 0.3
Phenonip® 0,8Phenonip ® 0.8
Gluadin® WQ 0,5Gluadin WQ ® 0.5
Gluadin® WLM 0,8Gluadin® ® WLM 0.8
Pantolacton 1 ,0 Subtilisin oder Papain 0,8Pantolactone 1, 0 Subtilisin or papain 0.8
Parfümöl 0,25Perfume oil 0.25
Wasser ad 100 pH = 7,0Water ad 100 pH = 7.0
Beispiel 7:Example 7:
Shampoo (in % ):Shampoo (in%):
Laurethsulfat 25% 40Laureth sulfate 25% 40
Citronensäure 0,1Citric acid 0.1
Natriumbenzoat 0,5Sodium benzoate 0.5
Disodium Cocoamphodiacetate 6,0Disodium Cocoamphodiacetate 6.0
Salicylsäure 0,1Salicylic acid 0.1
Hydrotriticum®WQ 1 ,0Hydrotriticum ® WQ 1, 0
Gluadin® WQ 0,2Gluadin WQ ® 0.2
Gluadin® WLM 0,5Gluadin ® WLM 0.5
Pantolacton 0,5Pantolactone 0.5
Subtilisin Oder Papain 0,2Subtilisin or papain 0.2
Cetiol® HE 0,5Cetiol ® HE 0.5
Parfüm 0,4Perfume 0.4
NaCI 0,5 Wasser Ad 100NaCl 0.5 water Ad 100
Beispiel 8:Example 8:
Shampoo (in % ):Shampoo (in%):
Laurethsulfat 25%(Alkalische Verdünnung) 25,0Laureth sulfate 25% (alkaline dilution) 25.0
Citric Acid Mono Regulär 0,3Citric Acid Mono Regular 0.3
Timiron® 0,5Timiron ® 0.5
Natriumbenzoat 0,5Sodium benzoate 0.5
Panthenol 75 L 0,2 Euperlan® PK 3000 8,0Panthenol 75 L 0.2 Euperlan PK 3000 ® 8.0
Plantacare® 818 UP 2,0Plantacare ® 818 UP 2.0
Uvinui® MS40 1 ,0Uvinui ® MS40 1 0
Salicylsäure 0,2Salicylic acid 0.2
Ajidew® NI-50 2,0Ajidew ® NI-50 2.0
Cutina® HR Gemahlen 0,5Cutina ® HR Ground 0.5
Cetiol® HE 1 ,0 Zitronensäure 0,03Cetiol ® HE 1, 0 Citric acid 0.03
Jaguar® Excel 0,3 Jaguar® Excel 0.3
Gluadin® WQ 0,2Gluadin WQ ® 0.2
Gluadin® WLM 0,5Gluadin ® WLM 0.5
Pantolacton 0,5Pantolactone 0.5
Subtilisin oder Papain 0,5Subtilisin or papain 0.5
Natriumchlorid 0,3 Wasser Ad 100Sodium chloride 0.3 water Ad 100
Beispiel 9:Example 9:
Shampoo (in % ):Shampoo (in%):
Laurethsulfat 25%(Alkalische Verdünnung) 50Laureth sulfate 25% (alkaline dilution) 50
Citronensäure 0,4Citric acid 0.4
Arlypon® F 0,5Arlypon F ® 0.5
Antil®171 0,3Antil ® 171 0.3
Weizenproteinhydrolysat Kationisiert 1 ,5Wheat protein hydrolyzate Cationized 1, 5
Natriumbenzoat 0,5Sodium benzoate 0.5
Euperlan® PK 3000 6,0Euperlan ® PK 3000 6.0
Cocamidopropyl Betaine 45 % 5,0Cocamidopropyl Betaine 45% 5.0
Salicylsäure 0,2Salicylic acid 0.2
Silsoft® A-858 0,3Silsoft ® A-858 0.3
Gluadin® WQ 1.0Gluadin® ® WQ 1.0
Gluadin® WLM 1 ,0Gluadin® ® WLM 1, 0
Pantolacton 0,5 Subtilisin oder Papain 0,2Pantolactone 0.5 Subtilisin or papain 0.2
Cutina® HR 0,2Cutina ® HR 0.2
Cetiol® HE 1 ,0Cetiol ® HE 1, 0
Wasser Ad 100Water Ad 100
Beispiel 10:Example 10:
Haarstylinggel:hair styling gel:
Entsalztes Wasser ad 100Desalinated water ad 100
Synthalen® K 0,6Synthalen® ® K 0.6
Neutral® TE 0,5Neutral ® TE 0.5
Glyzerin 8,00Glycerin 8.00
Ethylalkohol Vergällt 96 VoI % FIs 30,00Ethyl alcohol denatured 96% by volume FIs 30.00
Gluadin® WQ 0,5Gluadin WQ ® 0.5
Gluadin® WLM 0,5Gluadin ® WLM 0.5
Pantolacton 1 ,0Pantolactone 1, 0
Subtilisin oder Papain 0,2Subtilisin or papain 0.2
Polyethylenglykol 2,00Polyethylene glycol 2.00
PVP/VA W-635 6,50PVP / VA W-635 6,50
Cremophor® RH 40 1 ,00Cremophor ® RH 40 1, 00
Parfüm 0,50 pH = 7,0Perfume 0.50 pH = 7.0
Beispiel 11 :Example 11:
Haarspray:Hairspray:
Amphomer® 3,00Amphomer ® 3.00
Luviskol® VA 37 16,00Luviskol ® VA 37 16.00
Amino-Methyl-PropanoMOO 0,60Amino-methyl-PropanoMOO 0.60
Isopropylmyristat 0,12Isopropyl myristate 0.12
Gluadin® WQ 0,5Gluadin WQ ® 0.5
Gluadin® WLM 0,5 Pantolacton 0,2Gluadin ® WLM 0.5 Pantolactone 0.2
Subtilisin oder Papain 1 ,0Subtilisin or papain 1, 0
Parfüm 0,20Perfume 0.20
Entsalztes Wasser ad 100Desalinated water ad 100
Ethylalkohol 67,50 pH = 7,0Ethyl alcohol 67.50 pH = 7.0
Beispiel 12:Example 12:
Haartonic:Hair Tonic:
Entsalztes Wasser ad 100Desalinated water ad 100
Panthenol 75 0,1Panthenol 75 0.1
Gluadin® WQ 0,2Gluadin WQ ® 0.2
Gluadin® WLM 0,5Gluadin ® WLM 0.5
Pantolacton 0,5Pantolactone 0.5
Subtilisin oder Papain 0,5Subtilisin or papain 0.5
Carbopol® 0,1Carbopol ® 0.1
Neutral® TE 0,10Neutral ® TE 0.10
Ethylalkohol 30,0 pH = 7,0Ethyl alcohol 30.0 pH = 7.0
Beispiel 13:Example 13:
Haarspülung wie in Bsp. 1 , als 2-K System : 1. Kammer:Hair conditioner as in example 1, as 2-K system: 1st chamber:
Eumulgin® B2 0,3Eumulgin ® B2 0.3
Cetyl/Stearylalkohol 3,3Cetyl / stearyl alcohol 3,3
Isopropylmyristat 0,5Isopropyl myristate 0.5
Paraffmöl perliquidum 15 cSt. DAB 9 0,3Paraffin oil perliquidum 15 cSt. DAB 9 0.3
Dehyquart®A-CA 2,0Dehyquart® ® A-CA 2.0
Gluadin® WQ 0,2Gluadin WQ ® 0.2
Gluadin® WLM 0,5 Pantolacton 0,5Gluadin ® WLM 0.5 Pantolactone 0.5
Phenonip® 0,8Phenonip ® 0.8
Wasser ad 100 pH = 4,0Water ad 100 pH = 4.0
2. Kammer2nd chamber
Subtilisin oder Papain 0,5Subtilisin or papain 0.5
(oder Papayaextrakt 1 ,0)(or papaya extract 1, 0)
Wasser ad 100Water ad 100
Beispiel 14:Example 14:
Haarkur analog Bsp. 6, aber in zwei Anwendungsschritten: Vorbehandlung mit EnzymConditioner analogous to Ex. 6, but in two application steps: pretreatment with enzyme
Subtilisin oder Papain 0,5Subtilisin or papain 0.5
(oder Papayaextrakt 1 ,0)(or papaya extract 1, 0)
Wasser ad 100Water ad 100
Nachbehandlung mit Pflege/Repairprodukt:Aftercare with care / repair product:
Sepigel®305 5,0Sepigel ® 305 5.0
Dow Corning®Q2-5220 5 cSt. 1 ,5Dow Corning ® Q2-5220 5 cSt. 1, 5
Genamin®DSAC 0,3Genamin DSAC ® 0.3
Phenonip® 0,8Phenonip ® 0.8
Gluadin® WQ 0,5Gluadin WQ ® 0.5
Gluadin® WLM 0,8Gluadin® ® WLM 0.8
Pantolacton 1 ,0Pantolactone 1, 0
Parfümöl 0,25Perfume oil 0.25
Wasser ad 100 Beispiel 15:Water ad 100 Example 15:
Prüfmuster :Test pattern:
Figure imgf000028_0001
Figure imgf000028_0001
Durchführung:Execution:
Vorbehandlung der Haarsträhnen :Pretreatment of the hair strands:
Die Haare (Alkinco 6634) wurden vor der Nullmessung mit einer Texapon® NSO - Lösung (ca. 10% AS) vorgereinigt und anschließend standard-dauergewellt. Das heißt es wurden 2 g Dauerwellgel (Poly-Lock 1) auf 1 g Haarsträhne verteilt. Anschließend wurde nach 40-minütigem Einwirken des Gels unter Standardbe¬ dingungen 60 Sekunden mit kaltem Leitungswasser gespült. Hiernach erfolgte die Fixierung mit 2 g Poly-Lock 2 pro 1 g Haar-strähne über einen Zeitraum von 10 Minuten.The hair (Alkinco 6634) were before the zero measurement with a Texapon.RTM ® NSO - pre-purified solution (10% AS) and then permed standard. That is, 2 g of permanent wave gel (Poly-Lock 1) were distributed over 1 g of hair strand. Subsequently, after 40 minutes of exposure to the gel under standard conditions, it was rinsed with cold tap water for 60 seconds. This was followed by fixing with 2 g of Poly-Lock 2 per 1 g of hair strand over a period of 10 minutes.
Produktapplikation :Product application:
Eine Haarsträhne wurde mit einer wässrigen Lösung von der jeweiligen Wirk¬ stoffmischung behandelt. Die Eintauchzeit betrug 15 Minuten bei Raumtempera¬ tur. Anschließend wurde das Haar 30 Sekunden unter kaltem, fließendem Lei¬ tungswasser ausgespült und luftgetrocknet. DSC-Messungen :A strand of hair was treated with an aqueous solution of the respective active ingredient mixture. The immersion time was 15 minutes at room temperature. The hair was then rinsed out for 30 seconds under cold, flowing water and air-dried. DSC measurements:
Zur Verifizierung des Repaireffektes wurden DSC-Messungen durchgeführt. Die Strähnen wurden in kleine Stücke (~ 1 mm) geschnitten und anschließend 5 Aliquots jeder Haarsträhne in die DSC-Messgefäße überführt. Nach Zugabe von aqua deion. erfolgten die Messungen in einem Temperaturbereich von 110-170 0C, bei 10°C/Min. Ermittelt wurden der Schmelzpunkt (Peak-Maximum in [0C]) und die Denaturierungsenthalpie (Fläche unter dem Peak in [J/g]).To verify the repair effect, DSC measurements were performed. The tresses were cut into small pieces (~ 1 mm) and then transferred to 5 aliquots of each strand of hair in the DSC measuring vessels. After adding aqua deion. The measurements were carried out in a temperature range of 110-170 0 C, at 10 ° C / min. The melting point (peak maximum in [ 0 C]) and the enthalpy of denaturation (area under the peak in [J / g]) were determined.
Es haben sich die folgenden Messwerte (Signifikanzniveau >99%) ergeben:The following measured values (significance level> 99%) have resulted:
1. Messreihe (Leave-on)1st series of measurements (leave-on)
Nullmessung 152,6°CZero measurement 152.6 ° C
Gluadin® WLM, Pantolacton, Exfocellia 153,8°CGluadin ® WLM, pantolactone, Exfocellia 153.8 ° C
2. Messreihe (Rinse-off)2nd series of measurements (rinse-off)
Nullmessung 151 ,90CZero measurement 151, 9 0 C
Gluadin® WLM und Exfocellia 153,70CGluadin® ® WLM and Exfocellia 153.7 0 C
Gluadin® WLM, Pantolacton, Exfocellia 154,2°CGluadin ® WLM, pantolactone, Exfocellia 154.2 ° C
Exfocellia (Vergleichsversuch) 152,7°C (keine signifikante Verbesserung)Exfocellia (comparative experiment) 152.7 ° C (no significant improvement)
3. Messreihe (Leave-on)3rd measurement series (leave-on)
Nullmessung 151 ,90CZero measurement 151, 9 0 C
Gluadin® WQ, Gluadin® WLM, Papaya Frucht HPG 153,00CGluadin® ® WQ, Gluadin® ® WLM, papaya fruit HPG 153.0 0 C
Gluadin® WLM, Papaya Frucht HPG 153,3°CGluadin ® WLM, Papaya Fruit HPG 153.3 ° C
Gluadin® WLM, Pantolacton, Papaya Frucht HPG 153,9°C 4. Messreihe (Leave-on)Gluadin® ® WLM, pantolactone, papaya fruit HPG 153.9 ° C 4th measurement series (leave-on)
Nullmessung 152,9°CZero measurement 152.9 ° C
Gluadin® WQ (Vergleichsversuch) 153,3°C (keine signifikante Verbesserung)Gluadin® ® WQ (Comparison) 153.3 ° C (no significant improvement)
Gluadin® WLM (Vergleichsversuch) 153,7°C (keine signifikante Verbesserung)Gluadin® ® WLM (Comparison) 153.7 ° C (no significant improvement)
δ.Messreihe (Rinse-off)δ.Measurements (Rinse-off)
Nullmessung 152,90CZero measurement 152.9 0 C
Gluadin® WLM, Papaya Frucht HPG, Pantolacton 154,4°CGluadin® ® WLM, papaya fruit HPG, pantolactone 154.4 ° C
6. Messreihe (Rinse-off)6th series of measurements (rinse-off)
Nullmessung 153,90CZero measurement 153.9 0 C
Gluadin® WQ (Vergleichsversuch) 153,6°C (keine signifikante Verbesserung)Gluadin® ® WQ (Comparison) 153.6 ° C (no significant improvement)
Gluadin® WLM (Vergleichsversuch) 154,6°C (keine signifikante Verbesserung)Gluadin® ® WLM (Comparison) 154.6 ° C (no significant improvement)
Verzeichnis der eingesetzten HandelsprodukteList of used commercial products
Die im Rahmen der Beispiele eingesetzten Handelsprodukte sind wie folgt defi¬ niert:The commercial products used in the examples are defined as follows:
Ajidew® NL50 Natriumsalz der Pyrrolidoncarbonsäure (ca. 48-52% Aktiv¬ substanzgehalt; INCI-Bezeichnung: Sodium PCA) (Ajino- moto)Ajidew ® NL50 sodium salt of pyrrolidone (substance content about 48-52% Aktiv¬; INCI name: Sodium PCA) (Ajino- moto)
Amphomer® INCI-Bezeichnung: Otylacrylamide/Acrylates/Butyl- aminoethyl Methacrylate Copolymer (National Starci) Antil® 171 Polyol-Fettsäure-Ester (INCI-Bezeichnung: PEG-18 Glyce- ryl Oleate/Cocoate) (Goldschmidt) Arlypon® F C12-14-Fettalkohol mit ca. 2,5-EO-Einheiten (INCI- Bezeichnung: Laureth-2) (Cognis) Biodocarb® 3-lod-2-proinyl-n-butylcarbamat (INCI-Bezeichnung: lo- dopropynyl Butylcarbamate) (Milker & Grüning)Amphomer ® INCI name: Otylacrylamide / Acrylates / Butyl aminoethyl Methacrylate Copolymer (National Starci) Antil ® 171 polyol fatty acid esters (INCI name: PEG-18 glyceryl ryl Oleate / Cocoate) (Goldschmidt) Arlypon F ® C12 14 fatty alcohol with about 2.5 EO-units (INCI name: Laureth-2) (Cognis) Biodocarb ® 3-iodo-2-n-proinyl butylcarbamate (INCI name: lo- dopropynyl Butylcarbamate) (Milker & Grüning)
Carbopol® Polyarcylsäure (INCI-Bezeichnung: Carbomer) (Noveon) Cetiol® HE Kokosmonglycerid mit ca. 7,3 EO-Einheiten (INCI- Bezeichnung: PEG-7 Glyceryl Cocoate) (Cognis) Cremophor® RH40 hydriertes Rizinusöl mit ca. 40-45 EO-Einheiten (INCI- Bezeichnung: PEG-40 Hydrogenated Castor OiI) (BASF) Cutina® HR gehärtetes Rizinusöl (INCI-Bezeichnung: Hydrogenated Castor OiI) (Cognis) Dehyquart® A-CA Trimethylhexadecylammoniumchlorid (ca. 24 -26 % Aktiv¬ substanz; INCI-Bezeichnung: Aqua (Water), Cetrimonium Chloride) (Cognis)Carbopol ® Polyarcylsäure (INCI name: Carbomer) (Noveon) Cetiol ® HE Kokosmonglycerid with about 7.3 EO units (INCI name: PEG-7 glyceryl cocoate) (Cognis) Cremophor ® RH40 hydrogenated castor oil with 40-45 EO units (INCI name: PEG-40 Hydrogenated Castor Oil) (BASF) Cutina ® HR hydrogenated castor oil (INCI name: Hydrogenated Castor Oil) (Cognis) Dehyquart® ® A- CA trimethylhexadecylammonium chloride (about 24-26% active substance; INCI name: Aqua (Water), Cetrimonium Chloride) (Cognis)
Dehyquart® F75 Fettalkohole-Methyltriethanolammoniummethylsulfat- dialkylester-Gemisch (INCI-Bezeichnung: Distearoylethyl Hydroxyethylmonium Methosulfate, Cetearyl Alcohol) (HENKEL) Dehyquart® L80 Bis(Cocoylethyl)-hydroxyethyl-methyl-ammonium- methosulfat (ca. 76 % Aktivsubstanz in Propylenglykol; INCI-Bezeichnung: Dicocoylethyl Hydroxyethylmonium Me- thosulfat, Propylene Glycol) (Henkel)Dehyquart ® F75 fatty alcohols Methyltriethanolammoniummethylsulfat--dialkyl-mixture (INCI name: Distearoylethyl Hydroxyethylmonium Methosulfate, Cetearyl Alcohol) (HENKEL) Dehyquart ® L80 bis (Cocoylethyl) -hydroxyethyl-methyl-ammonium methosulfate (approximately 76% active ingredient in propylene glycol; INCI Designation: dicocoylethyl hydroxyethylmonium methosulfate, propylene glycol) (Henkel)
Dow Corning® 200 Fluid Polydimethylsiloxan (INCI-Bezeichnung: Dimethicone) (Dow Corning) Dow Corning® Q2-5220 Silicon-Glykol-Copolymer (INCI-Bezeichnung: Dimethicone Copolyol) (Dow Corning) Eumulgin® B2 Cetylstearylalkohol mit ca. 20 EO-Einheiten (INCI- Bezeichnung: Ceteareth-20) (Cognis) Euperlan® PK3000 ca. 60-64% Festkörper; INCI-Bezeichnung: Glycol Distearate, Glycerin, Laureth-4, Cocamidopropyl Betaine) (Cognis)Dow Corning ® 200 fluid polydimethylsiloxane (INCI designation: Dimethicone) (Dow Corning) Dow Corning ® Q2-5220 silicone glycol copolymer (INCI name: dimethicone copolyol) (Dow Corning) Eumulgin B2 ® cetylstearyl alcohol with about 20 EO units (INCI name: Ceteareth-20) (Cognis) Euperlan ® PK3000 about 60-64% solids; INCI name: Glycol Distearate, Glycerol, Laureth-4, Cocamidopropyl Betaine) (Cognis)
Gafquat® 755 Dimethylaminoethylmethacrylat-Vinylpyrrolidon-Copolymer, quaterniert mit Diethylsulfat (ca. 19% Festkörper in Wasser; INCI-Bezeichnung: Polyquatemium-11) (ISP)Gafquat ® 755 dimethylaminoethyl methacrylate-vinylpyrrolidone copolymer, quaternized with diethyl sulfate (ca. 19% solids in water; INCI name: Polyquaternium-11) (ISP)
Genamin® DSAC Dimethyldistearylammoniumchlorid (INCI-Bezeichnung: Distearyldimonium Chloride) (Clariant)Genamin ® DSAC Dimethyldistearylammonium chloride (INCI name: Distearyldimonium Chloride) (Clariant)
Gluadin® WLM Weizenproteinhydrolysat (ca. 21-24% Festkörper; INCI- Bezeichnung: Hydrolyzed Wheat Protein) (Cognis)Gluadin ® WLM wheat protein hydrolyzate (about 21-24% solids, INCI name: Hydrolyzed Wheat Protein) (Cognis)
Gluadin® WQ Weizenproteinhydrolysat (ca. 31-35% Festkörper; INCI- Bezeichnung: Aqua (Water), Laurdimonium Hydroxypropyl Hydrolyzed Wheat Protein, Ethylparaben, Methylparaben) (Cognis)Gluadin ® WQ wheat protein hydrolyzate (about 31-35% solids, INCI name: Aqua (Water), Lauridimonium Hydroxypropyl Hydrolyzed Wheat Protein, Ethylparaben, Methylparaben) (Cognis)
Hydrotriticum® WQ ca. 26-30% Festkörper; INCI-Bezeichnung: Aqua (Water), Hydroxypropyltrimonium Hydrolyzed Wheat Protein; (Croda) Jaguar Excel® Guarhydroxypropyltrimethylammoniumchlorid (ca. 89% Aktivsubstanzgehalt; INCI-Bezeichnung: Guar Hydroxypro¬ pyltrimonium Chloride) (Rhodia) Neutral® TE N,N,N',N',-Tetrakis-(2-hydroxypropyl)-ethylendiamin (INCI- Bezeichnung: Tetrahydroxypropyl Ethylenediamine) (BASF) Phenonip10 Hydroxybenzoesäuremethylester-Hydroxybenzoe- säureethylester-Hydroxybenzoesäurepropylester- Hydroxybenzoesäurebutylester-Phenoxyethanol-Gemisch (ca. 28 % Aktivsubstanz; INCI-Bezeichnung: Phenoxyetha- nol, Methylparaben, Ethylparaben, Propylparaben, Butylpa- raben) (NIPA)Hydrotriticum ® WQ approx. 26-30% solids; INCI name: Aqua (Water), Hydroxypropyltrimonium Hydrolyzed Wheat Protein; (Croda) Jaguar Excel ® Guarhydroxypropyltrimethylammoniumchlorid (about 89% active substance content; INCI name: Guar Hydroxypro¬ pyltrimonium Chloride) (Rhodia) Neutral ® TE N, N, N ', N', - tetrakis (2-hydroxypropyl) ethylenediamine (INCI name: tetrahydroxypropyl ethylene diamine) (BASF) Phenonip 10 hydroxybenzoic acid methyl ester hydroxybenzoic acid ethylester hydroxybenzoic acid propyl ester hydroxybenzoic acid butyl ester phenoxyethanol mixture (about 28% active ingredient, INCI name: phenoxyethanol, methylparaben, ethylparaben, propylparaben, butylparaben) (NIPA)
Plantacare® 818UP C8-14-Alkylpolyglucosid (ca. 51-53% Akticsubstanzgehalt; INCI-Bezeichnung: Coco-Glucoside, Aqua (Water)) (Cog- nis) PVP/VA W-635 Vinylpyrrolidon Vinylacetat Copolymer (Ca.48-52% Fest¬ körper in Wasser ; INCI-Bezeichnung : VP/VA Copolymer) (ISP) Rewoquat® W75 l-Methyl-2-nortalgalkyl-3-talgfettsäureamidoethyl- imidazolinium-methosulfat (ca. 75 % Aktivsubstanz in Pro- pylenglykol; INCI-Bezeichnung: Quaternium-27, Propylene Glycol) (WITCO)Plantacare ® 818UP C8-14 alkyl polyglucoside (ca. 51-53% Akticsubstanzgehalt; INCI name: Coco-Glucoside, Aqua (Water)) (Cog nis) PVP / VA W-635 vinyl pyrrolidone vinyl acetate copolymer (Ca.48-52 % Fest¬ body in water; INCI name: VP / VA copolymer) (ISP) Rewoquat W75 ® l-methyl-2-nortalgalkyl-3-talgfettsäureamidoethyl- imidazolinium methosulphate (75% active substance in production pylenglykol; INCI Name: Quaternium-27, Propylene Glycol) (WITCO)
Salcare® SC 96 ca. 50% Aktivsubstanzgehalt; INCI-Bezeichnung: Polyqua- ternium-37, Propylene Glycol Dicaprylate/Dicaprate, PPG-1 Trideceth-6 (CIBA)Salcare ® SC 96 about 50% active ingredient content; INCI name: Polyquaternium-37, Propylene Glycol Dicaprylate / Dicaprate, PPG-1 Trideceth-6 (CIBA)
Sepigel® 305 ca. 45-49% Festkörper; INCI-Bezeichnung: Polyacryl¬ amide, C13-14 Isoparaffin, Laureth-7) (Seppic) Silsoft® A 858 INCI-Bezeichnung: DEA PG-Propyl PEG/PPG-18/21 Dime- thicone) (GE Silicones) Synthalen® K Polyacrylsäure (ca. 89% Aktivsubstanzgehalt; INCI- Bezeichnung: Carbomer) (3V Sigma) Uvinul® MS40 2-Hydroxy-4-methoxybenzophenon-5-sulfonsäure (100% Aktivsubstanzgehalt; INCI-Bezeichnung: Benzophenone- 4)(BASF) Sepigel ® 305 about 45-49% solids; INCI name: polyacrylamides amides, C13-14 isoparaffin, laureth-7) (Seppic) Silsoft ® A 858 INCI name: DEA PG-propyl PEG / PPG-18/21 dimethyl thicone) (GE Silicones) Synthalen ® K polyacrylic acid (ca. 89% active substance content; INCI name: Carbomer) (3V Sigma) Uvinul ® MS40 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid (100% active substance content; INCI name: Benzophenone- 4) (BASF)

Claims

Patentansprüche claims
1. Mittel zur Behandlung keratinischer Fasern, enthaltend mindestens eine Pro¬ tease und mindestens eine weitere Komponente, die ausgewählt ist unter Pro¬ teinhydrolysaten sowie Vitaminen, Provitaminen und Vitaminvorstufen sowie deren Derivaten.1. A composition for the treatment of keratinic fibers, containing at least one protease and at least one further component which is selected from protein tolysates and vitamins, provitamins and vitamin precursors and derivatives thereof.
2. Mittel nach Anspruch 1 , dadurch gekennzeichnet, dass die Protease ausge¬ wählt ist unter Serin Endopeptidasen und Cystein Endopeptidasen, insbeson¬ dere unter Subtilisin, Papain und Bromelain.2. Composition according to claim 1, characterized in that the protease is selected from among serine endopeptidases and cysteine endopeptidases, in particular under subtilisin, papain and bromelain.
3. Mittel nach Anspruch 1 oder 2, dadurch gekennzeichnet, dass die Enzyme in Mengen von 0,005 bis 10 Gew.-%, bezogen auf die gesamte Zubereitung, enthalten sind, insbesondere in. Mengen von 0,01 bis 5 Gew.-%.3. Composition according to claim 1 or 2, characterized in that the enzymes in amounts of 0.005 to 10 wt .-%, based on the total preparation, are contained, in particular in. Amounts of 0.01 to 5 wt .-%.
4. Mittel nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass die mindestens eine weitere Komponente in Mengen von 0,005 bis 10 Gew.-%, bezogen auf die gesamte Zubereitung, enthalten ist, vorzugsweise in. Mengen von 0,01 bis 2 Gew.-%.4. Composition according to one of the preceding claims, characterized in that the at least one further component in amounts of 0.005 to 10 wt .-%, based on the total preparation, is contained, preferably in. Amounts of 0.01 to 2 wt. -%.
5. Mittel nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass es mindestens ein Proteinhydrolysat und mindestens ein Vitamin, Pro¬ vitamin oder eine Vitaminvorstufe sowie eines deren Derivate enthält.5. Composition according to one of the preceding claims, characterized in that it contains at least one protein hydrolyzate and at least one vitamin, vitamin Pro or a vitamin precursor and one of their derivatives.
6. Mittel nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass es als Vitamin, Provitamin oder eine Vitaminvorstufe sowie eines deren Derivate Pantolacton enthält.6. Composition according to one of the preceding claims, characterized in that it contains as vitamin, provitamin or a vitamin precursor and one of their derivatives pantolactone.
7. Mittel nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass es mindestens ein kationisches Proteinhydrolysat enthält. 7. Composition according to one of the preceding claims, characterized in that it contains at least one cationic protein hydrolyzate.
8. Mittel nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass es mindestens ein Weizenproteinhydrolysat enthält.8. Composition according to one of the preceding claims, characterized in that it contains at least one wheat protein hydrolyzate.
9. Mittel nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass es mindestens ein kationisches sowie mindestens ein nichtionisches Proteinhydrolysat enthält.9. Composition according to one of the preceding claims, characterized in that it contains at least one cationic and at least one nonionic protein hydrolyzate.
10. Mittel nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass es Pantolacton, ein kationisches sowie ein nichtionisches Weizenpro¬ teinhydrolysat enthält.10. Composition according to one of the preceding claims, characterized in that it contains pantolactone, a cationic and a nonionic Weizenpro¬ teinhydrolysat.
11.Mittel nach einem der vorhergehenden Ansprüche, dadurch gekennzeichnet, dass es als Einkammersystem oder als Zweikammersystem konfektioniert vorliegt, wobei bei einem Zweikammersystem die Enzymkomponente und die Repairstαffkomponente räumlich voneinander getrennt sind.11.Mittel according to any one of the preceding claims, characterized in that it is made up as Einkammersystem or as a two-chamber system, wherein in a two-chamber system, the enzyme component and the Repairstαffkomponente are spatially separated.
12. Verwendung von mindestens einer Protease und mindestens einer weiteren Komponente, die ausgewählt ist unter Proteinhydrolysaten sowie Vitaminen, Provitaminen und Vitaminvorstufen sowie deren Derivaten zur Verbesserung der Struktur keratinischer Fasern.12. Use of at least one protease and at least one further component which is selected from protein hydrolysates as well as vitamins, provitamins and vitamin precursors and derivatives thereof for improving the structure of keratinic fibers.
13. Verfahren zur Verbesserung der Struktur keratinischer Fasern, dadurch ge¬ kennzeichnet, dass man ein erfindungsgemäßes Mittel auf die keratinischen Fasern aufbringt.13. A process for improving the structure of keratinic fibers, characterized ge indicates that applying an inventive agent to the keratinic fibers.
14. Zweiteiliges Kit zur Behandlung keratinischer Fasern, dadurch gekennzeich¬ net, dass es a) einen ersten Bereich, enthaltend die Protease und b) einen zweiten Bereich, enthaltend die eine weitere Komponente, die aus¬ gewählt ist unter Proteinhydrolysaten sowie Vitaminen, Provitaminen und Vitaminvorstufen sowie deren Derivaten, umfasst. 14. A two-part kit for the treatment of keratinic fibers, characterized gekennzeich¬ net, that a) a first region containing the protease and b) a second region containing the one further component aus¬ selected from protein hydrolysates and vitamins, provitamins and Vitamin precursors and their derivatives.
PCT/EP2005/008875 2004-08-26 2005-08-16 Novel agent for treating keratin fibres WO2006021350A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE200410041573 DE102004041573A1 (en) 2004-08-26 2004-08-26 New agent for the treatment of keratinic fibers
DE102004041573.0 2004-08-26

Publications (1)

Publication Number Publication Date
WO2006021350A1 true WO2006021350A1 (en) 2006-03-02

Family

ID=35207774

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/008875 WO2006021350A1 (en) 2004-08-26 2005-08-16 Novel agent for treating keratin fibres

Country Status (2)

Country Link
DE (1) DE102004041573A1 (en)
WO (1) WO2006021350A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006094309A2 (en) * 2005-03-04 2006-09-08 The Procter & Gamble Company Rinse-off or wipe-off skin cleansing compositions
FR2949969A1 (en) * 2009-09-11 2011-03-18 Svr Lab COSMETIC COMPOSITION BASED ON PURE UREA, USE AND CORRESPONDING APPLICATION METHOD
US8147853B2 (en) 2005-02-15 2012-04-03 The Procter & Gamble Company Personal care compositions containing hydrophobically modified non-platelet particles
CN103431172A (en) * 2013-08-27 2013-12-11 江苏康科食品工程技术有限公司 Preparation method of wheat protein peptide

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9745543B2 (en) * 2012-09-10 2017-08-29 Ecolab Usa Inc. Stable liquid manual dishwashing compositions containing enzymes

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508707A (en) * 1981-11-09 1985-04-02 Kakudai Shosan Kabushiki Kaisha Hair tonic composition
US5738879A (en) * 1995-11-15 1998-04-14 Rine; Jasper M. Scalp hair treatment method and composition
DE19649098A1 (en) * 1996-11-27 1998-05-28 Beiersdorf Ag Pharmaceutical, cosmetic and other compositions containing protease
US6106828A (en) * 1996-02-15 2000-08-22 Novo Nordisk A/S Conjugation of polypeptides
US6245342B1 (en) * 1996-12-12 2001-06-12 Lancaster Group Gmbh Cosmetic preparation with a peptide addition
WO2002022102A1 (en) * 2000-09-13 2002-03-21 The Procter & Gamble Company Cosmetic compositions
WO2002022100A1 (en) * 2000-09-13 2002-03-21 The Procter & Gamble Company Cosmetic method
FR2817475A1 (en) * 2000-12-04 2002-06-07 Rocher Yves Biolog Vegetale Use of a composition, comprises proteases and a retinol source to combat skin aging
US6416769B1 (en) * 2000-03-03 2002-07-09 Australian Importers, Ltd. Cosmetic compositions comprising exfoliating enzymes and uses thereof
JP2004182687A (en) * 2002-12-05 2004-07-02 Kao Corp Elastase inhibitor

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508707A (en) * 1981-11-09 1985-04-02 Kakudai Shosan Kabushiki Kaisha Hair tonic composition
US5738879A (en) * 1995-11-15 1998-04-14 Rine; Jasper M. Scalp hair treatment method and composition
US6106828A (en) * 1996-02-15 2000-08-22 Novo Nordisk A/S Conjugation of polypeptides
DE19649098A1 (en) * 1996-11-27 1998-05-28 Beiersdorf Ag Pharmaceutical, cosmetic and other compositions containing protease
US6245342B1 (en) * 1996-12-12 2001-06-12 Lancaster Group Gmbh Cosmetic preparation with a peptide addition
US6416769B1 (en) * 2000-03-03 2002-07-09 Australian Importers, Ltd. Cosmetic compositions comprising exfoliating enzymes and uses thereof
WO2002022102A1 (en) * 2000-09-13 2002-03-21 The Procter & Gamble Company Cosmetic compositions
WO2002022100A1 (en) * 2000-09-13 2002-03-21 The Procter & Gamble Company Cosmetic method
FR2817475A1 (en) * 2000-12-04 2002-06-07 Rocher Yves Biolog Vegetale Use of a composition, comprises proteases and a retinol source to combat skin aging
JP2004182687A (en) * 2002-12-05 2004-07-02 Kao Corp Elastase inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 2003, no. 12 5 December 2003 (2003-12-05) *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8147853B2 (en) 2005-02-15 2012-04-03 The Procter & Gamble Company Personal care compositions containing hydrophobically modified non-platelet particles
WO2006094309A2 (en) * 2005-03-04 2006-09-08 The Procter & Gamble Company Rinse-off or wipe-off skin cleansing compositions
WO2006094309A3 (en) * 2005-03-04 2006-11-23 Procter & Gamble Rinse-off or wipe-off skin cleansing compositions
WO2006096677A3 (en) * 2005-03-04 2007-02-15 Procter & Gamble Rinse-off or wipe-off skin cleansing compositions
US8563491B2 (en) 2005-03-04 2013-10-22 The Procter & Gamble Company Methods of cleansing skin and rinse-off or wipe-off compositions therefor
US9237995B2 (en) 2005-03-04 2016-01-19 The Procter & Gamble Company Methods of cleansing skin and rinse-off or wipe-off compositions therefor
FR2949969A1 (en) * 2009-09-11 2011-03-18 Svr Lab COSMETIC COMPOSITION BASED ON PURE UREA, USE AND CORRESPONDING APPLICATION METHOD
CN103431172A (en) * 2013-08-27 2013-12-11 江苏康科食品工程技术有限公司 Preparation method of wheat protein peptide

Also Published As

Publication number Publication date
DE102004041573A1 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
EP2020227B1 (en) Cationic cellulose derivatives for cosmetics
EP1276451B2 (en) Use of sugar surfactants and fatty acid partial glycerides
EP1812117B1 (en) Method for restructuring keratin fibers
EP2429483B1 (en) Hair care product containing acetylpyridinium salts
EP1594448B1 (en) Hair treatment agents with surfactant mixtures
DE10022077A1 (en) Compositions for use as hair or skin cosmetics or as cleaning agents for e.g. glass, metals, plastics or leather contain 2-furanone derivatives
DE102005031705A1 (en) Composition containing L-carnitine or L-carnitine derivatives and at least one further substance selected from taurine and its derivatives and at least one active substance obtainable from plants of the genus Echinacea
WO2000061066A2 (en) Cosmetic product and its use
EP1779845B1 (en) Use of cationic cellulose derivatives in cosmetics
EP1594449B1 (en) Hair treatment agents
DE102006056664A1 (en) Use of quercetin
WO2006021350A1 (en) Novel agent for treating keratin fibres
WO2008043644A2 (en) Use of dandelion extract for thickening hair and stimulating hair growth
DE19823552A1 (en) Preparation for the treatment of human skin and human hair with a special combination of active ingredients and use of this combination of active ingredients
DE102004024509B4 (en) Procedures and preparations for the restructuring of hair
EP2429484B1 (en) Hair care agent containing acetylpyridinium salts
DE102005061727A1 (en) Tinting agent based on plant dyes
DE102004045253A1 (en) New cationic diagonally cross linked copolymer useful for improving physical characteristics of keratinic fibers (preferably human hair) and for styling and conditioning hairs
WO2008031685A1 (en) Root extract of harpagophytum for stimulating hair growth
DE19717687A1 (en) Preparation for the treatment of keratinic fibers
DE4317576A1 (en) Hair after-treatment composition
WO2008031684A1 (en) Apium graveleons extract for stimulating hair growth
EP1637123A1 (en) Preparation for the enzymatic liberation in situ of a conditioning agent for keratin fibres
DE102006042232A1 (en) Biochinones to stimulate keratin synthesis
DE102009002285A1 (en) Scalp-friendly shampoos and conditioners

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase